<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="; font-style : italic;} Eur Respir JEur. Respir. JERJerjThe European" exact="Respiratory" post="Journal0903-19361399-3003European Respiratory Society pmcid: 7527651 doi: 10.1183/13993003.01727-2020ERJ-01727-2020 Version of"/>
 <result pre=": italic;} Eur Respir JEur. Respir. JERJerjThe European Respiratory Journal0903-19361399-3003European" exact="Respiratory" post="Society pmcid: 7527651 doi: 10.1183/13993003.01727-2020ERJ-01727-2020 Version of Record :"/>
 <result pre="7527651 doi: 10.1183/13993003.01727-2020ERJ-01727-2020 Version of Record : Task Force Report" exact="Epidemic" post="and pandemic viral infections: impact on tuberculosis and the"/>
 <result pre="Version of Record : Task Force Report Epidemic and pandemic" exact="viral" post="infections: impact on tuberculosis and the lungA consensus by"/>
 <result pre="Task Force Report Epidemic and pandemic viral infections: impact on" exact="tuberculosis" post="and the lungA consensus by the World Association for"/>
 <result pre="tuberculosis and the lungA consensus by the World Association for" exact="Infectious" post="Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN),"/>
 <result pre="and the lungA consensus by the World Association for Infectious" exact="Diseases" post="and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and"/>
 <result pre="lungA consensus by the World Association for Infectious Diseases and" exact="Immunological" post="Disorders (WAidid), Global Tuberculosis Network (GTN), and members of"/>
 <result pre="consensus by the World Association for Infectious Diseases and Immunological" exact="Disorders" post="(WAidid), Global Tuberculosis Network (GTN), and members of the"/>
 <result pre="World Association for Infectious Diseases and Immunological Disorders (WAidid), Global" exact="Tuberculosis" post="Network (GTN), and members of the European Society of"/>
 <result pre="and members of the European Society of Clinical Microbiology and" exact="Infectious" post="Diseases Study Group for Mycobacterial Infections (ESGMYC) Epidemic and"/>
 <result pre="members of the European Society of Clinical Microbiology and Infectious" exact="Diseases" post="Study Group for Mycobacterial Infections (ESGMYC) Epidemic and pandemic"/>
 <result pre="of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial" exact="Infections" post="(ESGMYC) Epidemic and pandemic viral infections: impact on TB"/>
 <result pre="Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC)" exact="Epidemic" post="and pandemic viral infections: impact on TB and the"/>
 <result pre="Diseases Study Group for Mycobacterial Infections (ESGMYC) Epidemic and pandemic" exact="viral" post="infections: impact on TB and the lung https://orcid.org/0000-0003-1103-0451OngCatherine Wei"/>
 <result pre="Epidemiology and Preclinical Research Dept, â€œL. Spallanzaniâ€� National Institute for" exact="Infectious" post="Diseases (INMI), IRCCS, Via Portuense 292, 00149, Rome, Italy."/>
 <result pre="and Preclinical Research Dept, â€œL. Spallanzaniâ€� National Institute for Infectious" exact="Diseases" post="(INMI), IRCCS, Via Portuense 292, 00149, Rome, Italy. E-mail:"/>
 <result pre="epidemics, including some that qualify as pandemics, such as severe" exact="acute" post="respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV,"/>
 <result pre="including some that qualify as pandemics, such as severe acute" exact="respiratory" post="syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza"/>
 <result pre="some that qualify as pandemics, such as severe acute respiratory" exact="syndrome" post="(SARS), Middle East respiratory syndrome (MERS), HIV, influenza A"/>
 <result pre="pandemics, such as severe acute respiratory syndrome (SARS), Middle East" exact="respiratory" post="syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently"/>
 <result pre="such as severe acute respiratory syndrome (SARS), Middle East respiratory" exact="syndrome" post="(MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19,"/>
 <result pre="influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung." exact="Tuberculosis" post="(TB) remains the top infectious disease killer, but apart"/>
 <result pre="recently COVID-19, affect the lung. Tuberculosis (TB) remains the top" exact="infectious disease" post="killer, but apart from syndemic TB/HIV little is known"/>
 <result pre="COVID-19, affect the lung. Tuberculosis (TB) remains the top infectious" exact="disease" post="killer, but apart from syndemic TB/HIV little is known"/>
 <result pre="from syndemic TB/HIV little is known regarding the interaction of" exact="viral" post="epidemics and pandemics with TB. The aim of this"/>
 <result pre="of this consensus-based document is to describe the effects of" exact="viral" post="infections resulting in epidemics and pandemics that affect the"/>
 <result pre="this consensus-based document is to describe the effects of viral" exact="infections" post="resulting in epidemics and pandemics that affect the lung"/>
 <result pre="writing committee of international experts including the European Centre for" exact="Disease" post="Prevention and Control Public Health Emergency (ECDC PHE) team,"/>
 <result pre="Public Health Emergency (ECDC PHE) team, the World Association for" exact="Infectious" post="Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network"/>
 <result pre="Health Emergency (ECDC PHE) team, the World Association for Infectious" exact="Diseases" post="and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN),"/>
 <result pre="(ECDC PHE) team, the World Association for Infectious Diseases and" exact="Immunological" post="Disorders (WAidid), the Global Tuberculosis Network (GTN), and members"/>
 <result pre="PHE) team, the World Association for Infectious Diseases and Immunological" exact="Disorders" post="(WAidid), the Global Tuberculosis Network (GTN), and members of"/>
 <result pre="Association for Infectious Diseases and Immunological Disorders (WAidid), the Global" exact="Tuberculosis" post="Network (GTN), and members of the European Society of"/>
 <result pre="and members of the European Society of Clinical Microbiology and" exact="Infectious" post="Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was"/>
 <result pre="members of the European Society of Clinical Microbiology and Infectious" exact="Diseases" post="(ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was established."/>
 <result pre="Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial" exact="Infections" post="(ESGMYC) was established. Consensus was achieved after multiple rounds"/>
 <result pre="the definitive consensus elements. The epidemiology and immunology of these" exact="viral" post="infections and their interactions with TB are discussed with"/>
 <result pre="definitive consensus elements. The epidemiology and immunology of these viral" exact="infections" post="and their interactions with TB are discussed with implications"/>
 <result pre="discussed with implications for diagnosis, treatment and prevention of airborne" exact="infections" post="(infection control, viral containment and workplace safety). This consensus"/>
 <result pre="for diagnosis, treatment and prevention of airborne infections (infection control," exact="viral" post="containment and workplace safety). This consensus document represents a"/>
 <result pre="the topic. This consensus statement describes the effects of the" exact="viral" post="infections resulting in epidemics and pandemics affecting the lung"/>
 <result pre="topic. This consensus statement describes the effects of the viral" exact="infections" post="resulting in epidemics and pandemics affecting the lung (MERS,"/>
 <result pre="(H1N1)pdm/09 and COVID-19) and their interactions with TB, the top" exact="infectious disease" post="killerhttps://bit.ly/2UUjhGu Funding Italian Ministry of HealthRicerca Corrente (Linea 1"/>
 <result pre="and COVID-19) and their interactions with TB, the top infectious" exact="disease" post="killerhttps://bit.ly/2UUjhGu Funding Italian Ministry of HealthRicerca Corrente (Linea 1"/>
 <result pre="qualify as pandemics, caused by old diseases such as cholera," exact="plague" post="and yellow fever, as well as emerging diseases such"/>
 <result pre="pandemics, caused by old diseases such as cholera, plague and" exact="yellow fever," post="as well as emerging diseases such as severe acute"/>
 <result pre="yellow fever, as well as emerging diseases such as severe" exact="acute" post="respiratory syndrome (SARS), Ebola, Zika, Middle East respiratory syndrome"/>
 <result pre="fever, as well as emerging diseases such as severe acute" exact="respiratory" post="syndrome (SARS), Ebola, Zika, Middle East respiratory syndrome (MERS),"/>
 <result pre="as well as emerging diseases such as severe acute respiratory" exact="syndrome" post="(SARS), Ebola, Zika, Middle East respiratory syndrome (MERS), HIV"/>
 <result pre="as severe acute respiratory syndrome (SARS), Ebola, Zika, Middle East" exact="respiratory" post="syndrome (MERS), HIV (although technically endemic), influenza A (H1N1)pdm/09"/>
 <result pre="severe acute respiratory syndrome (SARS), Ebola, Zika, Middle East respiratory" exact="syndrome" post="(MERS), HIV (although technically endemic), influenza A (H1N1)pdm/09 and"/>
 <result pre="most recently COVID-19. Several of these viruses affect the lung." exact="Tuberculosis" post="(TB) remains the top infectious disease killer caused by"/>
 <result pre="these viruses affect the lung. Tuberculosis (TB) remains the top" exact="infectious disease" post="killer caused by a single organism and was responsible"/>
 <result pre="viruses affect the lung. Tuberculosis (TB) remains the top infectious" exact="disease" post="killer caused by a single organism and was responsible"/>
 <result pre="syndemic TB/HIV, little is known regarding the interaction of other" exact="viral" post="epidemics with TB. This consensus-based document describes the effects"/>
 <result pre="TB. This consensus-based document describes the effects of the main" exact="viral" post="epidemics which predominately affect the lungs or cause systemic"/>
 <result pre="main viral epidemics which predominately affect the lungs or cause" exact="systemic" post="immunosuppression (MERS, SARS, HIV, influenza A(H1N1)pdm/09 and COVID-19) and"/>
 <result pre="fruit of a collaborative project involving the European Centre for" exact="Disease" post="Prevention and Control Public Health Emergency (ECDC PHE) team,"/>
 <result pre="Public Health Emergency (ECDC PHE) team, the World Association for" exact="Infectious" post="Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network"/>
 <result pre="Health Emergency (ECDC PHE) team, the World Association for Infectious" exact="Diseases" post="and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN),"/>
 <result pre="(ECDC PHE) team, the World Association for Infectious Diseases and" exact="Immunological" post="Disorders (WAidid), the Global Tuberculosis Network (GTN), and members"/>
 <result pre="PHE) team, the World Association for Infectious Diseases and Immunological" exact="Disorders" post="(WAidid), the Global Tuberculosis Network (GTN), and members of"/>
 <result pre="Association for Infectious Diseases and Immunological Disorders (WAidid), the Global" exact="Tuberculosis" post="Network (GTN), and members of the European Society of"/>
 <result pre="and members of the European Society of Clinical Microbiology and" exact="Infectious" post="Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC). Methods"/>
 <result pre="members of the European Society of Clinical Microbiology and Infectious" exact="Diseases" post="(ESCMID) Study Group for Mycobacterial Infections (ESGMYC). Methods We"/>
 <result pre="Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial" exact="Infections" post="(ESGMYC). Methods We performed a rapid and nonsystematic search"/>
 <result pre="references from an electronic database (PubMed), existing guidelines on TB," exact="viral" post="diseases and airborne diseases, and grey literature from their"/>
 <result pre="available information on prevention, diagnosis and treatment of TB and" exact="pulmonary" post="viral diseases was selected by the experts and summarised,"/>
 <result pre="information on prevention, diagnosis and treatment of TB and pulmonary" exact="viral" post="diseases was selected by the experts and summarised, and"/>
 <result pre="examples were provided to critically discuss the public health response." exact="Viral" post="diseases of the lung Epidemiology Viral respiratory infections are"/>
 <result pre="the public health response. Viral diseases of the lung Epidemiology" exact="Viral" post="respiratory infections are a major public health concern due"/>
 <result pre="public health response. Viral diseases of the lung Epidemiology Viral" exact="respiratory" post="infections are a major public health concern due to"/>
 <result pre="health response. Viral diseases of the lung Epidemiology Viral respiratory" exact="infections" post="are a major public health concern due to the"/>
 <result pre="droplets, or indirectly by contact with contaminated surfaces [3]. Large" exact="respiratory" post="droplets are generated primarily during coughing, sneezing and talking,"/>
 <result pre="droplets containing microorganisms from an infected person are expelled a" exact="short" post="distance through the air and deposited on another individual's"/>
 <result pre="through the air and deposited on another individual's conjunctivae, nasal" exact="mucosa" post="or mouth. Large droplets fall quickly onto surfaces close"/>
 <result pre="the infected person, increasing the risk of contact transmission. Moreover," exact="viral" post="infections can also be transmitted via aerosol particles of"/>
 <result pre="infected person, increasing the risk of contact transmission. Moreover, viral" exact="infections" post="can also be transmitted via aerosol particles of small"/>
 <result pre="via aerosol particles of small size (&amp;lt;5â€&quot;10â€…Âµm) which may be" exact="infectious" post="at a distance of several metres [4â€&quot;7]. Recent evidence"/>
 <result pre="[8], being detected for several hours on different surfaces [9]." exact="Respiratory" post="infections can be classified by the causative virus (e.g."/>
 <result pre="being detected for several hours on different surfaces [9]. Respiratory" exact="infections" post="can be classified by the causative virus (e.g. influenza)"/>
 <result pre="fever, nonproductive cough, coryza, sneezing, dyspnoea, myalgia, fatigue and nonexudative" exact="pharyngitis" post="[10]. The clinical spectrum can encompass asymptomatic infection, upper"/>
 <result pre="nonexudative pharyngitis [10]. The clinical spectrum can encompass asymptomatic infection," exact="upper respiratory tract infection" post="and lower respiratory tract infection that can result in"/>
 <result pre="pharyngitis [10]. The clinical spectrum can encompass asymptomatic infection, upper" exact="respiratory" post="tract infection and lower respiratory tract infection that can"/>
 <result pre="The clinical spectrum can encompass asymptomatic infection, upper respiratory tract" exact="infection" post="and lower respiratory tract infection that can result in"/>
 <result pre="spectrum can encompass asymptomatic infection, upper respiratory tract infection and" exact="lower" post="respiratory tract infection that can result in pneumonia or"/>
 <result pre="can encompass asymptomatic infection, upper respiratory tract infection and lower" exact="respiratory" post="tract infection that can result in pneumonia or acute"/>
 <result pre="asymptomatic infection, upper respiratory tract infection and lower respiratory tract" exact="infection" post="that can result in pneumonia or acute respiratory distress"/>
 <result pre="infection and lower respiratory tract infection that can result in" exact="pneumonia" post="or acute respiratory distress [11], and systemic infection [12]."/>
 <result pre="lower respiratory tract infection that can result in pneumonia or" exact="acute" post="respiratory distress [11], and systemic infection [12]. The severity"/>
 <result pre="respiratory tract infection that can result in pneumonia or acute" exact="respiratory" post="distress [11], and systemic infection [12]. The severity of"/>
 <result pre="can result in pneumonia or acute respiratory distress [11], and" exact="systemic" post="infection [12]. The severity of viral respiratory illness varies"/>
 <result pre="result in pneumonia or acute respiratory distress [11], and systemic" exact="infection" post="[12]. The severity of viral respiratory illness varies widely"/>
 <result pre="respiratory distress [11], and systemic infection [12]. The severity of" exact="viral" post="respiratory illness varies widely and severe disease is more"/>
 <result pre="distress [11], and systemic infection [12]. The severity of viral" exact="respiratory" post="illness varies widely and severe disease is more likely"/>
 <result pre="The severity of viral respiratory illness varies widely and severe" exact="disease" post="is more likely in older patients with or without"/>
 <result pre="patients with or without comorbidities. Infants may have more severe" exact="disease" post="for some organisms. Morbidity may result directly from viral"/>
 <result pre="severe disease for some organisms. Morbidity may result directly from" exact="viral infection," post="or may be due to exacerbation of other chronic"/>
 <result pre="viral infection, or may be due to exacerbation of other" exact="chronic" post="medical conditions or bacterial superinfection [13, 14]. The spread"/>
 <result pre="be due to exacerbation of other chronic medical conditions or" exact="bacterial" post="superinfection [13, 14]. The spread of respiratory virus infections"/>
 <result pre="medical conditions or bacterial superinfection [13, 14]. The spread of" exact="respiratory" post="virus infections varies between countries and regions, depending on"/>
 <result pre="or bacterial superinfection [13, 14]. The spread of respiratory virus" exact="infections" post="varies between countries and regions, depending on differences in"/>
 <result pre="socioeconomic status [15â€&quot;17]. Immunology The first line of defence against" exact="respiratory" post="viral infections includes intrinsic defences such as mucus and"/>
 <result pre="status [15â€&quot;17]. Immunology The first line of defence against respiratory" exact="viral" post="infections includes intrinsic defences such as mucus and antiviral"/>
 <result pre="[15â€&quot;17]. Immunology The first line of defence against respiratory viral" exact="infections" post="includes intrinsic defences such as mucus and antiviral peptides."/>
 <result pre="and antiviral peptides. When these are circumvented, viruses enter the" exact="epithelial" post="cells by recognising viral components via Toll-like receptors and"/>
 <result pre="these are circumvented, viruses enter the epithelial cells by recognising" exact="viral" post="components via Toll-like receptors and intracellular receptors (figure 1)"/>
 <result pre="to environmental substances and pathogens. The early protection response to" exact="respiratory" post="viruses includes mucus, surfactants and antiviral peptides that can"/>
 <result pre="surfactants and antiviral peptides that can prevent initial attachment and" exact="viral" post="entry. Respiratory viruses enter via the respiratory epithelium. Epithelial"/>
 <result pre="antiviral peptides that can prevent initial attachment and viral entry." exact="Respiratory" post="viruses enter via the respiratory epithelium. Epithelial cells have"/>
 <result pre="initial attachment and viral entry. Respiratory viruses enter via the" exact="respiratory" post="epithelium. Epithelial cells have a key role in initiating"/>
 <result pre="a key role in initiating the immune response by recognising" exact="viral" post="components (pathogen-associated molecular patterns (PAMPs)) via Toll-like receptors (TLRs)"/>
 <result pre="sensors trigger a signalling cascade resulting in the upregulation of" exact="type I" post="and III interferon (IFN) and the inflammatory response. This"/>
 <result pre="responses and of the antiviral state. The adaptive response to" exact="respiratory" post="viruses is mediated by both T- and B-cell compartments."/>
 <result pre="the B-cell response. B-cells produce antibodies that may neutralise the" exact="respiratory" post="viruses directly by binding to viral surface proteins that"/>
 <result pre="that may neutralise the respiratory viruses directly by binding to" exact="viral" post="surface proteins that are essential for entry of the"/>
 <result pre="Antibodies are in the form of IgA, mainly in the" exact="upper" post="respiratory tract, or IgG, in the lower respiratory tract."/>
 <result pre="are in the form of IgA, mainly in the upper" exact="respiratory" post="tract, or IgG, in the lower respiratory tract. Viral"/>
 <result pre="mainly in the upper respiratory tract, or IgG, in the" exact="lower" post="respiratory tract. Viral clearance is also mediated by CD8+-specific"/>
 <result pre="in the upper respiratory tract, or IgG, in the lower" exact="respiratory" post="tract. Viral clearance is also mediated by CD8+-specific T-cells"/>
 <result pre="upper respiratory tract, or IgG, in the lower respiratory tract." exact="Viral" post="clearance is also mediated by CD8+-specific T-cells with cytolytic"/>
 <result pre="T-regulatory (Treg) cell subsets, work to balance tissue damage and" exact="viral" post="clearance. TNF: tumour necrosis factor; CTL: cytotoxic T-lymphocyte; TFH:"/>
 <result pre="generation of the B-cell response and cell-mediated immunity leading to" exact="viral" post="clearance. In particular, B-cells produce antibodies that may neutralise"/>
 <result pre="clearance. In particular, B-cells produce antibodies that may neutralise the" exact="respiratory" post="viruses directly by binding to viral surface proteins or"/>
 <result pre="that may neutralise the respiratory viruses directly by binding to" exact="viral" post="surface proteins or activating the complement cascade (figure 1)"/>
 <result pre="protective immunity helping B-cells produce antibodies against foreign pathogens [22]." exact="Viral" post="clearance is also mediated by CD8+-specific T-cells with cytolytic"/>
 <result pre="activity. The protective antiviral T-cell response is a T-helper cell" exact="type 1" post="(Th1) response mainly mediated through interferon (IFN)-Î³ production [22â€&quot;25]."/>
 <result pre="are different, both in their composition and functional responsiveness to" exact="infectious diseases" post="[27, 28]. Regarding the response to Mycobacterium tuberculosis, after"/>
 <result pre="after mycobacterial dissemination to the lymph nodes, dendritic cells present" exact="bacterial" post="antigens to T-cells and prime them [29, 30]. Priming"/>
 <result pre="fibrotic capsule to generate a hypoxic environment to prevent M." exact="tuberculosis" post="growth [32], with hypoxia potentially worsening tissue destruction in"/>
 <result pre="a hypoxic environment to prevent M. tuberculosis growth [32], with" exact="hypoxia" post="potentially worsening tissue destruction in TB [33]. CD4 Th1"/>
 <result pre="relatively smaller role of CD8+ T-cells in protection against M." exact="tuberculosis" post="infection [37], and an even smaller contribution of B-cells"/>
 <result pre="smaller role of CD8+ T-cells in protection against M. tuberculosis" exact="infection" post="[37], and an even smaller contribution of B-cells and"/>
 <result pre="-infected patients [35, 42, 45], and in response to recent" exact="infections" post="[43, 44]. Increased CD8 T-cell response is associated with"/>
 <result pre="42, 45], and in response to recent infections [43, 44]." exact="Increased" post="CD8 T-cell response is associated with M. tuberculosis load"/>
 <result pre="[43, 44]. Increased CD8 T-cell response is associated with M." exact="tuberculosis" post="load and longitudinal studies have shown a decrease of"/>
 <result pre="trials, BCG reduced infant mortality by around 40% [49] and" exact="respiratory" post="infections other than TB by 70% in adolescents [50]."/>
 <result pre="BCG reduced infant mortality by around 40% [49] and respiratory" exact="infections" post="other than TB by 70% in adolescents [50]. These"/>
 <result pre="against viruses [52], and BCG-vaccinated healthy adults re-challenged with live" exact="yellow fever" post="vaccine showed improved antiviral immunity and decreased viral loads"/>
 <result pre="live yellow fever vaccine showed improved antiviral immunity and decreased" exact="viral" post="loads [53]. In mice, BCG vaccination protects against influenza"/>
 <result pre="[53]. In mice, BCG vaccination protects against influenza A, lowering" exact="viral" post="replication and lung injury [54, 55]. A recent ecological"/>
 <result pre="cheap and rapidly scalable preventive measure against COVID-19 and other" exact="viral" post="respiratory infections. Influenza H1N1 and lung disease The two"/>
 <result pre="and rapidly scalable preventive measure against COVID-19 and other viral" exact="respiratory" post="infections. Influenza H1N1 and lung disease The two most"/>
 <result pre="against COVID-19 and other viral respiratory infections. Influenza H1N1 and" exact="lung disease" post="The two most serious impacts of influenza virus on"/>
 <result pre="COVID-19 and other viral respiratory infections. Influenza H1N1 and lung" exact="disease" post="The two most serious impacts of influenza virus on"/>
 <result pre="of influenza virus on the lung are the development of" exact="pneumonia" post="and exacerbation of pre-existing pulmonary disease [60]. Such events"/>
 <result pre="lung are the development of pneumonia and exacerbation of pre-existing" exact="pulmonary" post="disease [60]. Such events seem rare and variable during"/>
 <result pre="are the development of pneumonia and exacerbation of pre-existing pulmonary" exact="disease" post="[60]. Such events seem rare and variable during most"/>
 <result pre="and 2009 pandemics, appears to cause more rapid and severe" exact="pneumonia" post="than other strains, with higher rates of bacterial superinfection"/>
 <result pre="and severe pneumonia than other strains, with higher rates of" exact="bacterial" post="superinfection [62]. H1N1 also affects the paediatric population [63,"/>
 <result pre="superinfection [62]. H1N1 also affects the paediatric population [63, 64]." exact="Primary" post="viral pneumonia is characterised by rapid onset of nonproductive"/>
 <result pre="[62]. H1N1 also affects the paediatric population [63, 64]. Primary" exact="viral pneumonia" post="is characterised by rapid onset of nonproductive cough, headache,"/>
 <result pre="H1N1 also affects the paediatric population [63, 64]. Primary viral" exact="pneumonia" post="is characterised by rapid onset of nonproductive cough, headache,"/>
 <result pre="by rapid onset of nonproductive cough, headache, myalgias, dyspnoea, tachypnoea," exact="hypoxia" post="and ground-glass opacities on computed tomography (CT) scans. Secondary"/>
 <result pre="tachypnoea, hypoxia and ground-glass opacities on computed tomography (CT) scans." exact="Secondary" post="bacterial pneumonia, which may occur concurrently or following the"/>
 <result pre="hypoxia and ground-glass opacities on computed tomography (CT) scans. Secondary" exact="bacterial pneumonia," post="which may occur concurrently or following the development of"/>
 <result pre="pneumonia, which may occur concurrently or following the development of" exact="viral pneumonia," post="is a frequent complication. Bacterial superinfection occurs through direct"/>
 <result pre="frequent complication. Bacterial superinfection occurs through direct damage of the" exact="respiratory" post="epithelium with modification of local and systemic immune defence."/>
 <result pre="damage of the respiratory epithelium with modification of local and" exact="systemic" post="immune defence. Bacterial superinfection, mainly due to Staphylococcus aureus"/>
 <result pre="recent Korean survey during the 2009 influenza A(H1N1)pdm/09 pandemic [66]." exact="Acute respiratory distress syndrome" post="(ARDS) and bacterial superinfection are two distinct clinicalâ€&quot;pathological syndromes"/>
 <result pre="Korean survey during the 2009 influenza A(H1N1)pdm/09 pandemic [66]. Acute" exact="respiratory" post="distress syndrome (ARDS) and bacterial superinfection are two distinct"/>
 <result pre="during the 2009 influenza A(H1N1)pdm/09 pandemic [66]. Acute respiratory distress" exact="syndrome" post="(ARDS) and bacterial superinfection are two distinct clinicalâ€&quot;pathological syndromes"/>
 <result pre="influenza A(H1N1)pdm/09 pandemic [66]. Acute respiratory distress syndrome (ARDS) and" exact="bacterial" post="superinfection are two distinct clinicalâ€&quot;pathological syndromes which have been"/>
 <result pre="ARDS was responsible for 10â€&quot;15% of the fatal cases, while" exact="bacterial" post="superinfection, with poorer prognosis with 85â€&quot;90% fatal cases, manifests"/>
 <result pre="superinfection, with poorer prognosis with 85â€&quot;90% fatal cases, manifests as" exact="acute" post="bronchopneumonia, with pathogenic bacteria cultured on autopsy [60, 62,"/>
 <result pre="with pathogenic bacteria cultured on autopsy [60, 62, 68]. Other" exact="viral" post="infections and lung disease (SARS and MERS) In recent"/>
 <result pre="pathogenic bacteria cultured on autopsy [60, 62, 68]. Other viral" exact="infections" post="and lung disease (SARS and MERS) In recent decades,"/>
 <result pre="cultured on autopsy [60, 62, 68]. Other viral infections and" exact="lung disease" post="(SARS and MERS) In recent decades, previously unknown zoonotic"/>
 <result pre="on autopsy [60, 62, 68]. Other viral infections and lung" exact="disease" post="(SARS and MERS) In recent decades, previously unknown zoonotic"/>
 <result pre="disease (SARS and MERS) In recent decades, previously unknown zoonotic" exact="respiratory" post="tract infections with epidemic potential such as SARS and"/>
 <result pre="and MERS) In recent decades, previously unknown zoonotic respiratory tract" exact="infections" post="with epidemic potential such as SARS and MERS have"/>
 <result pre="and highly pathogenic [69]. The low pathogenic coronaviruses infect the" exact="upper" post="respiratory tract and cause â€œflu-likeâ€� mild respiratory illness, while"/>
 <result pre="highly pathogenic [69]. The low pathogenic coronaviruses infect the upper" exact="respiratory" post="tract and cause â€œflu-likeâ€� mild respiratory illness, while highly"/>
 <result pre="coronaviruses infect the upper respiratory tract and cause â€œflu-likeâ€� mild" exact="respiratory" post="illness, while highly pathogenic coronaviruses (SARS and MERS) predominantly"/>
 <result pre="while highly pathogenic coronaviruses (SARS and MERS) predominantly infect the" exact="lower" post="airways, often causing fatal pneumonia [69]. Severe coronavirus pneumonia"/>
 <result pre="and MERS) predominantly infect the lower airways, often causing fatal" exact="pneumonia" post="[69]. Severe coronavirus pneumonia is often associated with rapid"/>
 <result pre="predominantly infect the lower airways, often causing fatal pneumonia [69]." exact="Severe" post="coronavirus pneumonia is often associated with rapid virus replication,"/>
 <result pre="the lower airways, often causing fatal pneumonia [69]. Severe coronavirus" exact="pneumonia" post="is often associated with rapid virus replication, massive inflammatory"/>
 <result pre="massive inflammatory cell infiltration and elevated pro-inflammatory cytokine/chemokine responses producing" exact="acute" post="lung injury and ARDS. Recent studies in experimentally infected"/>
 <result pre="a crucial role for virus-induced immunopathological events in causing fatal" exact="pneumonia" post="following coronavirus infection [69]. High initial viral titres in"/>
 <result pre="for virus-induced immunopathological events in causing fatal pneumonia following coronavirus" exact="infection" post="[69]. High initial viral titres in the airways, age"/>
 <result pre="in causing fatal pneumonia following coronavirus infection [69]. High initial" exact="viral" post="titres in the airways, age and comorbidities (e.g. hypertension,"/>
 <result pre="in the airways, age and comorbidities (e.g. hypertension, diabetes, obesity," exact="heart" post="failure, renal failure, etc.) are associated with worse outcomes"/>
 <result pre="airways, age and comorbidities (e.g. hypertension, diabetes, obesity, heart failure," exact="renal failure," post="etc.) are associated with worse outcomes [70â€&quot;74]. SARS-CoV, which"/>
 <result pre="receptor [75], usually presents with three phases [76]: 1) rapid" exact="viral" post="replication with fever, cough and other nonspecific symptoms, disappearing"/>
 <result pre="and progression to pneumonia-like symptoms, despite a progressive decline of" exact="viral" post="replication; and 3) development of ARDS in around 20%"/>
 <result pre="cough, myalgia, shortness of breath and dyspnoea, often progressing to" exact="pneumonia" post="(ICU admission necessary) [73, 81]. It can also cause"/>
 <result pre="cause gastrointestinal symptoms (abdominal pain, vomiting and diarrhoea). COVID-19 and" exact="lung disease" post="According to a recent report from China, COVID-19, the"/>
 <result pre="gastrointestinal symptoms (abdominal pain, vomiting and diarrhoea). COVID-19 and lung" exact="disease" post="According to a recent report from China, COVID-19, the"/>
 <result pre="disease According to a recent report from China, COVID-19, the" exact="disease" post="caused by SARS-CoV-2, is characterised by three clinical patterns:"/>
 <result pre="by three clinical patterns: absence or paucity of symptoms, mild-to-moderate" exact="disease" post="and severe pneumonia requiring admission to the ICU [82]."/>
 <result pre="patterns: absence or paucity of symptoms, mild-to-moderate disease and severe" exact="pneumonia" post="requiring admission to the ICU [82]. Dyspnoea develops after"/>
 <result pre="suggests that while 25% of COVID-19 patients have comorbidities including" exact="chronic" post="obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart"/>
 <result pre="while 25% of COVID-19 patients have comorbidities including chronic obstructive" exact="pulmonary" post="disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular"/>
 <result pre="25% of COVID-19 patients have comorbidities including chronic obstructive pulmonary" exact="disease" post="(COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease"/>
 <result pre="COVID-19 patients have comorbidities including chronic obstructive pulmonary disease (COPD)," exact="diabetes mellitus," post="hypertension, coronary heart disease, cerebrovascular disease and malignancies, the"/>
 <result pre="comorbidities including chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension," exact="coronary heart disease," post="cerebrovascular disease and malignancies, the proportion is more than"/>
 <result pre="including chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary" exact="heart" post="disease, cerebrovascular disease and malignancies, the proportion is more"/>
 <result pre="obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease," exact="cerebrovascular disease" post="and malignancies, the proportion is more than 90% among"/>
 <result pre="pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular" exact="disease" post="and malignancies, the proportion is more than 90% among"/>
 <result pre="figure may change overtime due to better estimation of the" exact="total" post="number of infections [93]. Besides virological diagnosis, imaging by"/>
 <result pre="overtime due to better estimation of the total number of" exact="infections" post="[93]. Besides virological diagnosis, imaging by chest radiography, ultrasound"/>
 <result pre="total number of infections [93]. Besides virological diagnosis, imaging by" exact="chest" post="radiography, ultrasound and CT are important for diagnosis and"/>
 <result pre="opacity and consolidation [94]. The combination of CT scan findings," exact="respiratory" post="parameters (peripheral capillary oxygen saturation and arterial oxygen tension/inspiratory"/>
 <result pre="transfer. Lungs of dead COVID-19 patients showed oedema, proteinaceous exudate," exact="focal" post="reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration"/>
 <result pre="of dead COVID-19 patients showed oedema, proteinaceous exudate, focal reactive" exact="hyperplasia" post="of pneumocytes with patchy inflammatory cellular infiltration and multinucleated"/>
 <result pre="airspaces [96, 97]. A recent study reported autopsy cases contained" exact="diffuse" post="alveolar damage with mononuclear response (CD4+ aggregates) surrounding thrombosed"/>
 <result pre="vessels, in the presence of associated haemorrhages [98â€&quot;100]. HIV and" exact="lung disease" post="The spectrum of HIV-associated pulmonary diseases is broad and"/>
 <result pre="in the presence of associated haemorrhages [98â€&quot;100]. HIV and lung" exact="disease" post="The spectrum of HIV-associated pulmonary diseases is broad and"/>
 <result pre="haemorrhages [98â€&quot;100]. HIV and lung disease The spectrum of HIV-associated" exact="pulmonary" post="diseases is broad and the lungs are one of"/>
 <result pre="immunodeficiency, is important in guiding the aetiological evaluation of lung" exact="infections" post="[102]. Pulmonary TB infection and reactivation are more likely"/>
 <result pre="important in guiding the aetiological evaluation of lung infections [102]." exact="Pulmonary" post="TB infection and reactivation are more likely with a"/>
 <result pre="guiding the aetiological evaluation of lung infections [102]. Pulmonary TB" exact="infection" post="and reactivation are more likely with a CD4 count"/>
 <result pre="with a CD4 count below 500â€…cellsÂ·mLâˆ’1. Opportunistic infections, Pneumocystis jirovecii," exact="bacterial infections," post="Kaposi sarcoma and extrapulmonary/disseminated forms of TB occur mainly"/>
 <result pre="CD4 count below 500â€…cellsÂ·mLâˆ’1. Opportunistic infections, Pneumocystis jirovecii, bacterial infections," exact="Kaposi sarcoma" post="and extrapulmonary/disseminated forms of TB occur mainly in patients"/>
 <result pre="count below 500â€…cellsÂ·mLâˆ’1. Opportunistic infections, Pneumocystis jirovecii, bacterial infections, Kaposi" exact="sarcoma" post="and extrapulmonary/disseminated forms of TB occur mainly in patients"/>
 <result pre="T-cell counts below 200â€…cellsÂ·mLâˆ’1. Cytomegalovirus infection, Mycobacterium avium complex and" exact="aspergillosis" post="usually occur at CD4 counts below 50â€…cellsÂ·mLâˆ’1. Risk factors"/>
 <result pre="to consider are the geographical origin that predisposes to specific" exact="disease" post="(e.g. TB, coccidioidomycosis, paragonimiasis and histoplasmosis), adherence to antiretroviral"/>
 <result pre="geographical origin that predisposes to specific disease (e.g. TB, coccidioidomycosis," exact="paragonimiasis" post="and histoplasmosis), adherence to antiretroviral therapy, prescription of P."/>
 <result pre="prescription of P. jirovecii prophylaxis and presence of comorbidities. Community-acquired" exact="bacterial pneumonia" post="occurs at all stages of HIV infection, but is"/>
 <result pre="of P. jirovecii prophylaxis and presence of comorbidities. Community-acquired bacterial" exact="pneumonia" post="occurs at all stages of HIV infection, but is"/>
 <result pre="of comorbidities. Community-acquired bacterial pneumonia occurs at all stages of" exact="HIV infection," post="but is more frequent in patients with profound CD4"/>
 <result pre="profound CD4 T-cell depletion and decreases with antiretroviral therapy. Community-acquired" exact="pneumonia" post="accounts for 35â€&quot;50% of all hospital admission cases due"/>
 <result pre="accounts for 35â€&quot;50% of all hospital admission cases due to" exact="respiratory" post="failure and is the main reason for ICU admission"/>
 <result pre="is the main reason for ICU admission [103]. TB and" exact="respiratory" post="viral diseases TB and influenza The association of TB"/>
 <result pre="the main reason for ICU admission [103]. TB and respiratory" exact="viral" post="diseases TB and influenza The association of TB and"/>
 <result pre="TB and influenza could be bidirectional: TB may increase the" exact="susceptibility to" post="influenza and the risk of complications, and influenza may"/>
 <result pre="and the risk of complications, and influenza may increase the" exact="susceptibility to" post="TB. The susceptibility to influenza appears to be greater"/>
 <result pre="complications, and influenza may increase the susceptibility to TB. The" exact="susceptibility to" post="influenza appears to be greater in patients with pre-existing"/>
 <result pre="to influenza appears to be greater in patients with pre-existing" exact="pulmonary" post="disease (e.g. asthma and COPD). As a large proportion"/>
 <result pre="influenza appears to be greater in patients with pre-existing pulmonary" exact="disease" post="(e.g. asthma and COPD). As a large proportion of"/>
 <result pre="to be greater in patients with pre-existing pulmonary disease (e.g." exact="asthma" post="and COPD). As a large proportion of post-TB treatment"/>
 <result pre="COPD, which can be severe [104, 105], patients with such" exact="pulmonary" post="sequelae may be predisposed and more susceptible to influenza"/>
 <result pre="pulmonary sequelae may be predisposed and more susceptible to influenza" exact="infection" post="and its complications, including mortality [106]. Furthermore, the temporary"/>
 <result pre="South Africa [107]. TB patients have a similar prevalence of" exact="viral" post="and bacterial co-infection as their household contacts, but TB"/>
 <result pre="[107]. TB patients have a similar prevalence of viral and" exact="bacterial" post="co-infection as their household contacts, but TB patients often"/>
 <result pre="their household contacts, but TB patients often have more severe" exact="disease" post="if they are co-infected [108]. As early as 1919,"/>
 <result pre="was reported [109]. Influenza induces a temporary increase in the" exact="susceptibility to" post="bacterial infections, exemplified by the frequent occurrence of bacterial"/>
 <result pre="[109]. Influenza induces a temporary increase in the susceptibility to" exact="bacterial infections," post="exemplified by the frequent occurrence of bacterial pneumonia following"/>
 <result pre="susceptibility to bacterial infections, exemplified by the frequent occurrence of" exact="bacterial pneumonia" post="following viral pneumonitis [110]. Because influenza impairs the immune"/>
 <result pre="to bacterial infections, exemplified by the frequent occurrence of bacterial" exact="pneumonia" post="following viral pneumonitis [110]. Because influenza impairs the immune"/>
 <result pre="infections, exemplified by the frequent occurrence of bacterial pneumonia following" exact="viral" post="pneumonitis [110]. Because influenza impairs the immune response, it"/>
 <result pre="the development of active TB among patients with latent TB" exact="infection" post="(LTBI) [111]; however, the occurrence of TB may occur"/>
 <result pre="association difficult to demonstrate. There was an excess mortality from" exact="pulmonary" post="TB during the influenza pandemics of 1889 and 1918"/>
 <result pre="antiretroviral treatment, the risk of LTBI progressing to active TB" exact="disease" post="in people living with HIV and AIDS (PLWHA) is"/>
 <result pre="preventive treatment for all PLWHA [119, 120]. New regimens as" exact="short" post="as 1â€…month (daily rifapentine plus isoniazid) to 3â€…months (weekly"/>
 <result pre="[119, 120]. Important programmatic implications for collaboration between TB and" exact="HIV/AIDS" post="services exist: TB services should test for HIV (allowing"/>
 <result pre="and cotrimoxazole preventive therapy in patients with HIV/TB co-infection) and" exact="HIV/AIDS" post="services should screen for LTBI, using the tuberculin skin"/>
 <result pre="burden of HIV among TB patients. Moreover, testing for other" exact="infections" post="in addition to HIV in TB clinics may be"/>
 <result pre="different cohort of 236 SARS patients, two were diagnosed with" exact="pulmonary" post="TB [123]. The development of TB in the presence"/>
 <result pre="in the presence of SARS may be due to CD4" exact="lymphopenia" post="during the viral infection [124], as CD4+ T-cells are"/>
 <result pre="of SARS may be due to CD4 lymphopenia during the" exact="viral infection" post="[124], as CD4+ T-cells are crucial for TB-specific immunity"/>
 <result pre="SARS may be due to CD4 lymphopenia during the viral" exact="infection" post="[124], as CD4+ T-cells are crucial for TB-specific immunity"/>
 <result pre="[130]. This highlights the importance of remaining vigilant to other" exact="communicable diseases," post="including TB, when epidemic or pandemic infections dominate media"/>
 <result pre="to other communicable diseases, including TB, when epidemic or pandemic" exact="infections" post="dominate media headlines [131]. TB with MERS-CoV co-infection is"/>
 <result pre="TB patients [132], although it was unclear which the initial" exact="infection" post="was. TB and COVID-19 There may be interaction between"/>
 <result pre="an increased prevalence of LTBI in patients with severe COVID-19" exact="infection" post="and concluded that infection with M. tuberculosis may influence"/>
 <result pre="LTBI in patients with severe COVID-19 infection and concluded that" exact="infection" post="with M. tuberculosis may influence the progression and outcome"/>
 <result pre="with severe COVID-19 infection and concluded that infection with M." exact="tuberculosis" post="may influence the progression and outcome of COVID-19. Evidence"/>
 <result pre="Evidence on the interactions between TB and COVID-19 is needed." exact="Respiratory" post="viral diseases and TB in the elderly, prisoners and"/>
 <result pre="on the interactions between TB and COVID-19 is needed. Respiratory" exact="viral" post="diseases and TB in the elderly, prisoners and other"/>
 <result pre="may reside in high-density communal settings which can perpetuate rapid" exact="infectious disease" post="transmission during an epidemic or pandemic. Immunosenescence is an"/>
 <result pre="reside in high-density communal settings which can perpetuate rapid infectious" exact="disease" post="transmission during an epidemic or pandemic. Immunosenescence is an"/>
 <result pre="risk factor in the elderly [137]. Clinical presentation of these" exact="infections" post="in the elderly can be subtle, with atypical manifestation"/>
 <result pre="of these infections in the elderly can be subtle, with" exact="atypical" post="manifestation such as delirium, and may present with complications."/>
 <result pre="as delirium, and may present with complications. SARS and COVID-19" exact="respiratory" post="failure are well documented in the elderly [138, 139]."/>
 <result pre="of 4962 patients found elderly patients had less risk of" exact="respiratory" post="failure, ICU admission or mechanical ventilation [140]. For TB,"/>
 <result pre="immunocompromised and pregnant women may also present with complications including" exact="respiratory" post="failure when infected with pandemic H1N1 influenza or TB"/>
 <result pre="depend on available resources and on accessibility, which may be" exact="limited" post="to none for the homeless and the incarcerated, although"/>
 <result pre="The elderly may further have technical difficulties in providing quality" exact="respiratory" post="samples for testing, such as for TB, when they"/>
 <result pre="when they have an impaired cough response. A poor quality" exact="respiratory" post="sample inevitably delays diagnosis and contact tracing efforts. Treatment"/>
 <result pre="delays diagnosis and contact tracing efforts. Treatment and management of" exact="viral" post="infections and TB includes prompt isolation of presumptive cases"/>
 <result pre="diagnosis and contact tracing efforts. Treatment and management of viral" exact="infections" post="and TB includes prompt isolation of presumptive cases and"/>
 <result pre="mortality in the elderly [77, 138, 147]. Diagnostic challenges in" exact="viral" post="diseases and TB For prompt diagnosis of viruses causing"/>
 <result pre="diseases and TB For prompt diagnosis of viruses causing severe" exact="acute" post="respiratory infections [148], such as SARS-CoV, MERS-CoV and SARS-CoV-2"/>
 <result pre="and TB For prompt diagnosis of viruses causing severe acute" exact="respiratory" post="infections [148], such as SARS-CoV, MERS-CoV and SARS-CoV-2 [149â€&quot;152],"/>
 <result pre="TB For prompt diagnosis of viruses causing severe acute respiratory" exact="infections" post="[148], such as SARS-CoV, MERS-CoV and SARS-CoV-2 [149â€&quot;152], and"/>
 <result pre="SARS-CoV, MERS-CoV and SARS-CoV-2 [149â€&quot;152], and differentiation from other common" exact="bacterial infections," post="a strategic laboratory approach is needed. This approach requires"/>
 <result pre="surveillance systems [157]. For this purpose, developing protein microarrays to" exact="respiratory" post="virus serology is useful [153]. TABLE 1 Performance characteristics"/>
 <result pre="useful [153]. TABLE 1 Performance characteristics of diagnostic approaches to" exact="respiratory" post="infection Respiratory viruses Mycobacterium tuberculosis complex Sensitivity Specificity Time"/>
 <result pre="[153]. TABLE 1 Performance characteristics of diagnostic approaches to respiratory" exact="infection" post="Respiratory viruses Mycobacterium tuberculosis complex Sensitivity Specificity Time to"/>
 <result pre="TABLE 1 Performance characteristics of diagnostic approaches to respiratory infection" exact="Respiratory" post="viruses Mycobacterium tuberculosis complex Sensitivity Specificity Time to result#"/>
 <result pre="characteristics of diagnostic approaches to respiratory infection Respiratory viruses Mycobacterium" exact="tuberculosis" post="complex Sensitivity Specificity Time to result# User friendly Unknown"/>
 <result pre="&amp;lt;2â€…h; Â¶: metagenomics and whole-genome sequencing; +: immunofluorescence microscopy on" exact="respiratory" post="samples to detect the most common viruses, or Ziehlâ€&quot;Neelsen"/>
 <result pre="or Ziehlâ€&quot;Neelsen or auramine/rhodamine staining to detect acid-fast bacilli; Â§:" exact="viral" post="culture established in several eukaryotic cell lines and mycobacterial"/>
 <result pre="relies on direct detection of M. tuberculosis, most often in" exact="respiratory" post="specimens. Although culture remains the â€œgold standardâ€� in terms"/>
 <result pre="of sensitivity and specificity, effective molecular assays to detect M." exact="tuberculosis" post="DNA are also used on platforms and in point-of-care"/>
 <result pre="on platforms and in point-of-care tests [158]. Moreover, these M." exact="tuberculosis" post="molecular assays can detect mutations associated with resistance, rapidly"/>
 <result pre="molecular platforms that could be used for detecting pathogens in" exact="respiratory" post="specimens. The challenge lies in sample processing and RNA/DNA"/>
 <result pre="laboratories, producing an invaluable asset to improve diagnosis against other" exact="infections" post="including TB. At the same time, the expertise, tools"/>
 <result pre="the rapid implementation of molecular diagnosis of COVID-19 and other" exact="viral" post="infections. Tests (lateral flow assay and ELISA based) to"/>
 <result pre="and ELISA based) to rapidly detect antigens in swabs or" exact="respiratory" post="secretions and to determine serological evidence of recent and"/>
 <result pre="secretions and to determine serological evidence of recent and past" exact="infection" post="and evidence of neutralising antibodies are currently being evaluated."/>
 <result pre="being evaluated. Impact of new, potential and existing drugs for" exact="viral" post="diseases and COVID-19 on TB therapy 80% of COVID-19"/>
 <result pre="drugs for SARS-CoV-2, therapeutic approaches in severely ill patients are" exact="limited" post="to supportive care and empirical use of antibiotics to"/>
 <result pre="care and empirical use of antibiotics to prevent or treat" exact="secondary" post="infections [84, 86, 161]. To provide active treatment for"/>
 <result pre="and empirical use of antibiotics to prevent or treat secondary" exact="infections" post="[84, 86, 161]. To provide active treatment for SARS-CoV-2,"/>
 <result pre="161]. To provide active treatment for SARS-CoV-2, drugs potentially inhibiting" exact="viral" post="replication are of interest (figure 2) [162]. FIGURE 2"/>
 <result pre="2 Proposed mechanism of action of drugs used for severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 can enter the"/>
 <result pre="Proposed mechanism of action of drugs used for severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 can enter the cell"/>
 <result pre="mechanism of action of drugs used for severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). SARS-CoV-2 can enter the cell through"/>
 <result pre="can enter the cell through angiotensin-converting enzyme 2 (ACE2) and" exact="type II" post="transmembrane serine protease (TMPRSS2). Camostat mesylate acts as an"/>
 <result pre="as an inhibitor of TMPRSS2 and umifenovir can inhibit the" exact="viral" post="entry to the cell [180, 228, 229]. Chloroquine, hydroxychloroquine"/>
 <result pre="fully understood; however, it is proposed that these drugs affect" exact="viral" post="entry. Baricitinib also inhibits the AP-2-associated protein kinase [173,"/>
 <result pre="studied treatment for COVID-19, although evidence of efficacy is still" exact="limited" post="[164]. In non-TB patients, the combination, studied in an"/>
 <result pre="SARS-CoV-2 following promising in vitro results [162, 168]. In the" exact="absence of" post="results from well-designed clinical studies, clinical benefit is currently"/>
 <result pre="QTc prolongation. An ongoing trial was halted due to irregular" exact="heart" post="rates and increased risk of fatal heart arrhythmia [174]."/>
 <result pre="due to irregular heart rates and increased risk of fatal" exact="heart" post="arrhythmia [174]. The US Food and Drug Administration (FDA)"/>
 <result pre="to irregular heart rates and increased risk of fatal heart" exact="arrhythmia" post="[174]. The US Food and Drug Administration (FDA) has"/>
 <result pre="role of steroids to reduce ARDS in TB patients is" exact="limited" post="as data of good quality to support the use"/>
 <result pre="support the use of steroids outside the treatment of TB" exact="meningitis" post="is scarce [163]. Evidence on the use of steroids"/>
 <result pre="co-administered with other drugs in a separate study, in the" exact="absence of" post="real dedicated DDI studies. The summary includes effects on"/>
 <result pre="exposure, monitoring/action and potential mechanisms. TABLE 2 Drug interactions between" exact="tuberculosis" post="(TB) and potential COVID-19 medications WHO: World Health Organization;"/>
 <result pre="small RCT [185], and seems suitable for further development. Controlling" exact="viral" post="diseases and TB: strengths and opportunities Principles of viral"/>
 <result pre="Controlling viral diseases and TB: strengths and opportunities Principles of" exact="viral" post="containment Globalisation, increased urbanisation resulting in large vastly populated"/>
 <result pre="or a continent in just a few hours. In the" exact="absence of" post="a vaccine or an effective treatment, the tools to"/>
 <result pre="or an effective treatment, the tools to control a new" exact="viral infection" post="have remained the same as during the 1918 influenza"/>
 <result pre="an effective treatment, the tools to control a new viral" exact="infection" post="have remained the same as during the 1918 influenza"/>
 <result pre="designed to reduce the risk of transmission and spread of" exact="infection" post="such as increased respiratory hygiene, cough etiquette and hand"/>
 <result pre="risk of transmission and spread of infection such as increased" exact="respiratory" post="hygiene, cough etiquette and hand washing, voluntary isolation of"/>
 <result pre="measures, restrictions on travel and transportation, and dissemination of basic" exact="infection" post="prevention and control messages and advice to the general"/>
 <result pre="that, while potentially reducing transmission, may also result in the" exact="collapse" post="of the economy of a country. These nonpharmaceutical countermeasures"/>
 <result pre="COVID-19 by minimising the number of contacts that result in" exact="disease" post="transmission and, thus, reducing the effective reproduction number R0"/>
 <result pre="period of time. This approach, while not necessarily reducing the" exact="total" post="number of cases, gains time necessary for the development,"/>
 <result pre="necessary ICU equipment as well as more sensitive diagnostic tests." exact="Infection" post="control refers to the different methods and strategies deployed"/>
 <result pre="deployed to reduce or prevent the incidence and/or transmission of" exact="infections" post="(see the following subsection on â€œAirborne infection control and"/>
 <result pre="and/or transmission of infections (see the following subsection on â€œAirborne" exact="infection" post="control and workplace safetyâ€�). Containment, through early detection, investigation"/>
 <result pre="aims at containing, preventing or delaying the spread of the" exact="disease" post="in the community. Geographical containment in a defined area"/>
 <result pre="the area immediately surrounding the containment zone (buffer zone) for" exact="secondary" post="infections [186]. Delaying the spread of infection can be"/>
 <result pre="area immediately surrounding the containment zone (buffer zone) for secondary" exact="infections" post="[186]. Delaying the spread of infection can be achieved"/>
 <result pre="(buffer zone) for secondary infections [186]. Delaying the spread of" exact="infection" post="can be achieved by early identification and treatment of"/>
 <result pre="introduced early social isolation measures experienced a significant reduction of" exact="viral" post="spread, approximately 50% lower peak death rates and nearly"/>
 <result pre="measures experienced a significant reduction of viral spread, approximately 50%" exact="lower" post="peak death rates and nearly 20% lower cumulative excess"/>
 <result pre="spread, approximately 50% lower peak death rates and nearly 20%" exact="lower" post="cumulative excess mortality than cities that did not, with"/>
 <result pre="not, with a consequent reduction on healthcare pressures [187]. Airborne" exact="infection" post="control and workplace safety Airborne infection control in healthcare"/>
 <result pre="healthcare pressures [187]. Airborne infection control and workplace safety Airborne" exact="infection" post="control in healthcare settings uses a hierarchy of control"/>
 <result pre="administrative controls and personal protective equipment (i.e. surgical masks for" exact="infectious" post="patients and respirators for healthcare workers and visitors) [188â€&quot;190]."/>
 <result pre="TB guidelines [188, 189], but can be extended also for" exact="viral" post="infections including COVID-19 [191, 192]. As presently under discussion"/>
 <result pre="guidelines [188, 189], but can be extended also for viral" exact="infections" post="including COVID-19 [191, 192]. As presently under discussion in"/>
 <result pre="masks to limit the spread of droplet nuclei for isolated" exact="symptomatic" post="patients, the potential mass use of surgical masks to"/>
 <result pre="the community spread of COVID-19 during the early stages of" exact="infection" post="and from asymptomatic individuals is strongly discussed [191, 193,"/>
 <result pre="the potential risks of moisture retention, long mask re-use and" exact="limited" post="filtration capacity [195]. While the WHO is revising its"/>
 <result pre="by the general population may reduce the spread of the" exact="infection" post="in the community by minimising the excretion of respiratory"/>
 <result pre="the infection in the community by minimising the excretion of" exact="respiratory" post="droplets from infected individuals who have not yet developed"/>
 <result pre="developed symptoms or who remain asymptomatic [198]. In general, all" exact="infection" post="control measures are important to prevent infections and render"/>
 <result pre="In general, all infection control measures are important to prevent" exact="infections" post="and render workplaces safe. The stability of SARS-CoV-2 is"/>
 <result pre="spread and superspreading events since it can remain viable and" exact="infectious" post="in aerosols for hours and on surfaces up to"/>
 <result pre="days [199]. Current evidence provides support for direct contact and" exact="respiratory" post="droplets as predominant routes of SARS-CoV-2 transmission [200], and"/>
 <result pre="samples with an alkaline pH [202], more than 7â€…days in" exact="respiratory" post="secretions at room temperature, for at least 4â€…days in"/>
 <result pre="compared with cotton gowns [201]. Human coronavirus 229E can remain" exact="infectious" post="on high-touch environmental surfaces (polyvinylchloride, laminate, wood and stainless"/>
 <result pre="specific features of COVID-19, which spreads very rapidly with a" exact="short" post="incubation period and infects exponentially thousands of individuals in"/>
 <result pre="measures as discussed in the previous subsection on â€œPrinciples of" exact="viral" post="containmentâ€�. Human resources, equipment and new approaches to clinical"/>
 <result pre="and long-term consequences, particularly in resource-limited countries, with increases in" exact="malnutrition" post="and poverty-related diseases, which include TB. To mitigate the"/>
 <result pre="implementation of the emergency plan [211]. Impact of â€œfearâ€� of" exact="viral" post="infections on health services and TB services There are"/>
 <result pre="of the emergency plan [211]. Impact of â€œfearâ€� of viral" exact="infections" post="on health services and TB services There are many"/>
 <result pre="to TB diagnosis and care. Fear, defined as an instinctive" exact="emotional" post="reaction to a specific, identifiable and immediate threat such"/>
 <result pre="of all nonessential services including small clinics, movement restrictions and" exact="limited" post="access to public transport, police patrols, and enforced isolation"/>
 <result pre="on management of nonpandemic conditions including TB, strokes and myocardial" exact="infections" post="is not only because of the unwillingness of individuals"/>
 <result pre="(81%) countries had closed all educational institutions, higher education and" exact="secondary" post="schools, primary schools, and day care/nurseries; in some countries"/>
 <result pre="had closed all educational institutions, higher education and secondary schools," exact="primary" post="schools, and day care/nurseries; in some countries primary schools"/>
 <result pre="secondary schools, primary schools, and day care/nurseries; in some countries" exact="primary" post="schools (two out of 31 (6%)) and/or day care/nurseries"/>
 <result pre="recommendation (general population) Stay-at-home recommendation (risk group) Higher education and" exact="secondary" post="school Primary school Day care or nursery Austria âœ&quot;"/>
 <result pre="population) Stay-at-home recommendation (risk group) Higher education and secondary school" exact="Primary" post="school Day care or nursery Austria âœ&quot; âœ&quot; âœ&quot;"/>
 <result pre="etc.); closure of educational institutions (including day care or nursery," exact="primary" post="schools, and secondary schools and higher education); stay-at-home recommendations"/>
 <result pre="educational institutions (including day care or nursery, primary schools, and" exact="secondary" post="schools and higher education); stay-at-home recommendations for risk groups"/>
 <result pre="and COVID-19 [135, 136, 216]. Similarities and differences related to" exact="infection" post="control and workplace safety have been discussed. For diagnosis,"/>
 <result pre="Personal protective equipment is needed to protect laboratory personnel handling" exact="viral" post="specimens [135, 136]. Cough is the pivotal symptom to"/>
 <result pre="Cough is the pivotal symptom to diagnose TB. In the" exact="absence of" post="adequate diagnostic tools, the presence of cough, fever and"/>
 <result pre="nonspecific symptoms complicates differential diagnosis of TB, COVID-19 and other" exact="respiratory" post="infections [135]. The necessary physical distancing policies are likely"/>
 <result pre="symptoms complicates differential diagnosis of TB, COVID-19 and other respiratory" exact="infections" post="[135]. The necessary physical distancing policies are likely to"/>
 <result pre="COVID-19 pandemic may result in increased poverty, social disturbances and" exact="malnutrition" post="with a profound impact increasing TB incidence and mortality"/>
 <result pre="and determined action to contain the COVID-19 epidemic at its" exact="localised" post="or importation stage will give more time for reinforcement"/>
 <result pre="treatment needs will help to maximise the healthcare throughput with" exact="limited" post="resources. Simultaneous measures to contain the spread of the"/>
 <result pre="limit the mounting patient load and avoid major breaches in" exact="nosocomial infection" post="control and total collapse of the healthcare system. Breaking"/>
 <result pre="the mounting patient load and avoid major breaches in nosocomial" exact="infection" post="control and total collapse of the healthcare system. Breaking"/>
 <result pre="load and avoid major breaches in nosocomial infection control and" exact="total" post="collapse of the healthcare system. Breaking the transmission link"/>
 <result pre="and avoid major breaches in nosocomial infection control and total" exact="collapse" post="of the healthcare system. Breaking the transmission link is"/>
 <result pre="the transmission link is the main method for containing an" exact="infectious disease" post="in the absence of an effective vaccine. Controlling a"/>
 <result pre="transmission link is the main method for containing an infectious" exact="disease" post="in the absence of an effective vaccine. Controlling a"/>
 <result pre="the main method for containing an infectious disease in the" exact="absence of" post="an effective vaccine. Controlling a respiratory infection at source"/>
 <result pre="disease in the absence of an effective vaccine. Controlling a" exact="respiratory" post="infection at source is often more cost-effective than targeting"/>
 <result pre="in the absence of an effective vaccine. Controlling a respiratory" exact="infection" post="at source is often more cost-effective than targeting multiple"/>
 <result pre="The evidence for the protective effect of cloth masks is" exact="limited" post="and contradictory [195, 225]. For both diseases, early case"/>
 <result pre="stopped at source by effective treatment. Isolation for the whole" exact="infectious" post="period is needed to contain the spread of COVID-19."/>
 <result pre="relevance) MeanÂ± sd 1. Large droplets increase the risk of" exact="respiratory" post="viral infection through direct transmission. 0 (0.0) 6 (16.2)"/>
 <result pre="MeanÂ± sd 1. Large droplets increase the risk of respiratory" exact="viral infection" post="through direct transmission. 0 (0.0) 6 (16.2) 6 (16.2)"/>
 <result pre="sd 1. Large droplets increase the risk of respiratory viral" exact="infection" post="through direct transmission. 0 (0.0) 6 (16.2) 6 (16.2)"/>
 <result pre="6 (16.2) 6 (16.2) 10 (27.0) 15 (40.5) 3.9Â±1.1 2." exact="Respiratory" post="viral infections are more likely to occur in older"/>
 <result pre="(16.2) 6 (16.2) 10 (27.0) 15 (40.5) 3.9Â±1.1 2. Respiratory" exact="viral" post="infections are more likely to occur in older patients"/>
 <result pre="6 (16.2) 10 (27.0) 15 (40.5) 3.9Â±1.1 2. Respiratory viral" exact="infections" post="are more likely to occur in older patients (with"/>
 <result pre="(24.3) 3.6Â±1.1 3. Elderly patients are more likely to develop" exact="acute" post="respiratory distress syndrome and there is an age-related death"/>
 <result pre="3.6Â±1.1 3. Elderly patients are more likely to develop acute" exact="respiratory" post="distress syndrome and there is an age-related death risk."/>
 <result pre="Elderly patients are more likely to develop acute respiratory distress" exact="syndrome" post="and there is an age-related death risk. 0 (0.0)"/>
 <result pre="(10.8) 10 (27.0) 23 (62.2) 4.5Â±0.7 4. Antibodies might neutralise" exact="respiratory" post="viruses and, then, decrease the risk of recurrent infections."/>
 <result pre="might neutralise respiratory viruses and, then, decrease the risk of" exact="recurrent" post="infections. 0 (0.0) 4 (10.8) 7 (18.9) 17 (46.0)"/>
 <result pre="7 (18.9) 10 (27.0) 10 (27.0) 6 (16.2) 3.2Â±1.2 6." exact="Severe" post="COVID-19 is associated with rapid virus replication, massive inflammatory"/>
 <result pre="of CT scan findings (ground-glass opacity and consolidation), clinical presentation" exact="respiratory" post="parameters (SpO2 and PaO2/FIO2) and blood tests (C-reactive proteins,"/>
 <result pre="count is key to guide the aetiological evaluation of lung" exact="infections" post="in HIV-infected individuals. 0 (0.0) 3 (8.1) 7 (18.9)"/>
 <result pre="3.9Â±0.9 10. Temporary immunosuppression induced by TB might increase the" exact="susceptibility to" post="influenza viruses. 2 (5.4) 6 (16.2) 8 (21.6) 18"/>
 <result pre="the general population; N95 for HCWs performing aerosol-producing activities) on" exact="symptomatic" post="patients and their contacts can reduce the risk of"/>
 <result pre="patients and their contacts can reduce the risk of SARS-CoV-2" exact="infection" post="by limiting the spread of droplet nuclei from isolated"/>
 <result pre="infection by limiting the spread of droplet nuclei from isolated" exact="symptomatic" post="patients. 0 (0.0) 0 (0.0) 1 (2.7) 9 (24.3)"/>
 <result pre="(2.7) 9 (24.3) 27 (73.0) 4.7Â±0.5 15. SARS-CoV-2 virus remains" exact="infectious" post="in the environment on different surfaces for days. 0"/>
 <result pre="emergency plans can reduce the healthcare and socioeconomic burden of" exact="respiratory" post="viral infections resulting in epidemics/pandemics. 0 (0.0) 0 (0.0)"/>
 <result pre="plans can reduce the healthcare and socioeconomic burden of respiratory" exact="viral" post="infections resulting in epidemics/pandemics. 0 (0.0) 0 (0.0) 4"/>
 <result pre="can reduce the healthcare and socioeconomic burden of respiratory viral" exact="infections" post="resulting in epidemics/pandemics. 0 (0.0) 0 (0.0) 4 (10.8)"/>
 <result pre="stated. BCG: bacille Calmetteâ€&quot;GuÃ©rin; RCT: randomised controlled trial; SARS-CoV-2: severe" exact="acute" post="respiratory syndrome coronavirus 2; CT: computed tomography; SpO2: arterial"/>
 <result pre="BCG: bacille Calmetteâ€&quot;GuÃ©rin; RCT: randomised controlled trial; SARS-CoV-2: severe acute" exact="respiratory" post="syndrome coronavirus 2; CT: computed tomography; SpO2: arterial oxygen"/>
 <result pre="bacille Calmetteâ€&quot;GuÃ©rin; RCT: randomised controlled trial; SARS-CoV-2: severe acute respiratory" exact="syndrome" post="coronavirus 2; CT: computed tomography; SpO2: arterial oxygen saturation"/>
 <result pre="The scores, from the 37 questionnaires received, exceeded 3 (from" exact="intermediate" post="to highest score) in all of the 18 statements,"/>
 <result pre="consensus-based document we describe the effects of epidemic and pandemic" exact="viral" post="infections (SARS, MERS, influenza A (H1N1)pdm/09, HIV and COVID-19)"/>
 <result pre="document we describe the effects of epidemic and pandemic viral" exact="infections" post="(SARS, MERS, influenza A (H1N1)pdm/09, HIV and COVID-19) and"/>
 <result pre="were discussed, including drugs, DDIs, novel therapies, and principles of" exact="infection" post="control and workplace safety. COVID-19 and TB interactions were"/>
 <result pre="ERJ-01727-2020.Shareable.pdf LINK Acknowledgements The co-authors from the World Association of" exact="Infectious" post="Diseases and Immunological Disorders (WAidid) and Global Tuberculosis Network"/>
 <result pre="LINK Acknowledgements The co-authors from the World Association of Infectious" exact="Diseases" post="and Immunological Disorders (WAidid) and Global Tuberculosis Network (GTN)"/>
 <result pre="The co-authors from the World Association of Infectious Diseases and" exact="Immunological" post="Disorders (WAidid) and Global Tuberculosis Network (GTN) are: Jan-Willem"/>
 <result pre="co-authors from the World Association of Infectious Diseases and Immunological" exact="Disorders" post="(WAidid) and Global Tuberculosis Network (GTN) are: Jan-Willem Alffenaar,"/>
 <result pre="Association of Infectious Diseases and Immunological Disorders (WAidid) and Global" exact="Tuberculosis" post="Network (GTN) are: Jan-Willem Alffenaar, Emmanuelle Cambau, Rosella Centis,"/>
 <result pre="38 (95%) endorsed the document as follows. From the Global" exact="Tuberculosis" post="Network (GTN): Onno W. Akkerman (The Netherlands), Francois-Xavier Blanc"/>
 <result pre="Richard Zaleskis (Latvia). From the ESCMID Study Group for Mycobacterial" exact="Infections" post="(ESGMYC): Ana-Gil Brusola (Spain), Danilo Buonsenso (Italy), Paola Di"/>
 <result pre="co-Principal Investigator of the Pan-African Network on Emerging and Re-Emerging" exact="Infections" post="(PANDORA-IDNET) funded by the European and Developing Countries Clinical"/>
 <result pre="University Health System, Singapore (NUHS/RO/2017/092/SU/01, CFGFY18P11, NUHS/RO/2020/042/RO5+5/ad-hoc/1); National Centre for" exact="Infectious" post="Diseases, Singapore (STPRG-FY19-003); and is recipient of the Young"/>
 <result pre="The article is part of the activities of the Global" exact="Tuberculosis" post="Network (GTN) and of the WHO Collaborating Centre for"/>
 <result pre="Tuberculosis Network (GTN) and of the WHO Collaborating Centre for" exact="Tuberculosis" post="and Lung Diseases, Tradate (ITA-80, 2017-2020-GBM/RC/LDA). Part of the"/>
 <result pre="(GTN) and of the WHO Collaborating Centre for Tuberculosis and" exact="Lung Diseases," post="Tradate (ITA-80, 2017-2020-GBM/RC/LDA). Part of the work was supported"/>
 <result pre="has nothing to disclose. References References 1collab: World Health OrganizationGlobal" exact="tuberculosis" post="report 2019. Geneva, WHO, 2019. 2MiglioriGB, TiberiS, ZumlaA, et"/>
 <result pre="the new decade. The 2020 clinical update by the Global" exact="Tuberculosis" post="Network. Int J Infect Dis2020; 92S: S15â€&quot;S25. doi:10.1016/j.ijid.2020.01.04232032752 3YanJ,"/>
 <result pre="3YanJ, GranthamM, PantelicJ, et al.Infectious virus in exhaled breath of" exact="symptomatic" post="seasonal influenza cases from a college community. Proc Natl"/>
 <result pre="SARS-CoV-1. N Engl J Med2020; 382: 1564â€&quot;1567. doi:10.1056/NEJMc200497332182409 10ArnoldFW, FuquaJLViral" exact="respiratory" post="infections: a cause of community-acquired pneumonia or a predisposing"/>
 <result pre="1564â€&quot;1567. doi:10.1056/NEJMc200497332182409 10ArnoldFW, FuquaJLViral respiratory infections: a cause of community-acquired" exact="pneumonia" post="or a predisposing factor?Curr Opin Pulm Med2020; 26: 208â€&quot;214."/>
 <result pre="predisposing factor?Curr Opin Pulm Med2020; 26: 208â€&quot;214. doi:10.1097/MCP.000000000000066632068577 11JainSEpidemiology of" exact="viral pneumonia." post="Clin Chest Med2017; 38: 1â€&quot;9. doi:10.1016/j.ccm.2016.11.01228159152 12VargaZ, FlammerAJ, SteigerP,"/>
 <result pre="Med2017; 38: 1â€&quot;9. doi:10.1016/j.ccm.2016.11.01228159152 12VargaZ, FlammerAJ, SteigerP, et al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19. Lancet2020; 395: 1417â€&quot;1418. doi:10.1016/S0140-6736(20)30937-532325026 13JainS,"/>
 <result pre="COVID-19. Lancet2020; 395: 1417â€&quot;1418. doi:10.1016/S0140-6736(20)30937-532325026 13JainS, SelfWH, WunderinkRG, et al.Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. adults. N Engl J Med2015;"/>
 <result pre="J Med2015; 373: 415â€&quot;427. doi:10.1056/NEJMoa150024526172429 14JainS, WilliamsDJ, ArnoldSR, et al.Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. children. N Engl J Med2015;"/>
 <result pre="e0124122. doi:10.1371/journal.pone.012412225938466 17MadhiSA, De WalsP, GrijalvaCG, et al.The burden of" exact="childhood" post="pneumonia in the developed world: a review of the"/>
 <result pre="doi:10.1371/journal.pone.012412225938466 17MadhiSA, De WalsP, GrijalvaCG, et al.The burden of childhood" exact="pneumonia" post="in the developed world: a review of the literature."/>
 <result pre="EdwardsMR, et al.The airway epithelium: soldier in the fight against" exact="respiratory" post="viruses. Clin Microbiol Rev2011; 24: 210â€&quot;229. doi:10.1128/CMR.00014-1021233513 19OngCW, ElkingtonPT,"/>
 <result pre="viruses. Clin Microbiol Rev2011; 24: 210â€&quot;229. doi:10.1128/CMR.00014-1021233513 19OngCW, ElkingtonPT, FriedlandJSTuberculosis," exact="pulmonary" post="cavitation, and matrix metalloproteinases. Am J Respir Crit Care"/>
 <result pre="J Immunol2014; 193: 469â€&quot;475. doi:10.4049/jimmunol.140043224994909 21GuptaN, LeGoffJ, ChamatS, et al.Affinity-purified" exact="respiratory" post="syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent"/>
 <result pre="Opin Virol2013; 3: 468â€&quot;474. doi:10.1016/j.coviro.2013.05.00523806514 24KrishnamoorthyN, KhareA, OrissTB, et al.Early" exact="infection" post="with respiratory syncytial virus impairs regulatory T cell function"/>
 <result pre="3: 468â€&quot;474. doi:10.1016/j.coviro.2013.05.00523806514 24KrishnamoorthyN, KhareA, OrissTB, et al.Early infection with" exact="respiratory" post="syncytial virus impairs regulatory T cell function and increases"/>
 <result pre="respiratory syncytial virus impairs regulatory T cell function and increases" exact="susceptibility to" post="allergic asthma. Nat Med2012; 18: 1525â€&quot;1530. doi:10.1038/nm.289622961107 25BystromJ, Al-AdhoubiN,"/>
 <result pre="virus impairs regulatory T cell function and increases susceptibility to" exact="allergic asthma." post="Nat Med2012; 18: 1525â€&quot;1530. doi:10.1038/nm.289622961107 25BystromJ, Al-AdhoubiN, Al-BogamiM, et"/>
 <result pre="18: 1525â€&quot;1530. doi:10.1038/nm.289622961107 25BystromJ, Al-AdhoubiN, Al-BogamiM, et al.Th17 lymphocytes in" exact="respiratory" post="syncytial virus infection. Viruses2013; 5: 777â€&quot;791. doi:10.3390/v503077723462708 26Abril-RodriguezG, RibasASnapShot:"/>
 <result pre="doi:10.1038/nm.289622961107 25BystromJ, Al-AdhoubiN, Al-BogamiM, et al.Th17 lymphocytes in respiratory syncytial" exact="virus infection." post="Viruses2013; 5: 777â€&quot;791. doi:10.3390/v503077723462708 26Abril-RodriguezG, RibasASnapShot: immune checkpoint inhibitors."/>
 <result pre="infection. Viruses2013; 5: 777â€&quot;791. doi:10.3390/v503077723462708 26Abril-RodriguezG, RibasASnapShot: immune checkpoint inhibitors." exact="Cancer" post="Cell2017; 31: 848â€&quot;848. doi:10.1016/j.ccell.2017.05.01028609660 27SimonAK, HollanderGA, McMichaelAEvolution of the"/>
 <result pre="174: 1277â€&quot;1292. doi:10.1016/j.cell.2018.06.04530142345 29ChackerianAA, AltJM, PereraTV, et al.Dissemination of Mycobacterium" exact="tuberculosis" post="is influenced by host factors and precedes the initiation"/>
 <result pre="LinasB, et al.Initiation of the adaptive immune response to Mycobacterium" exact="tuberculosis" post="depends on antigen production in the local lymph node,"/>
 <result pre="WittmerST, et al.ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium" exact="tuberculosis" post="infection are initiated in the mediastinal lymph nodes. Proc"/>
 <result pre="et al.ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis" exact="infection" post="are initiated in the mediastinal lymph nodes. Proc Natl"/>
 <result pre="FarhanaA, GuidryL, et al.Redox homeostasis in mycobacteria: the key to" exact="tuberculosis" post="control?Expert Rev Mol Med2011; 13: e39. doi:10.1017/S146239941100207922172201 33OngCWM, FoxK,"/>
 <result pre="Sci Rep2018; 8: 11475. doi:10.1038/s41598-018-29659-130065292 34DwivediVP, BhattacharyaD, ChatterjeeS, et al.Mycobacterium" exact="tuberculosis" post="directs T helper 2 cell differentiation by inducing interleukin-1beta"/>
 <result pre="Chem2012; 287: 33656â€&quot;33663. doi:10.1074/jbc.M112.37515422810226 35PetruccioliE, ScribaTJ, PetroneL, et al.Correlates of" exact="tuberculosis" post="risk: predictive biomarkers for progression to active tuberculosis. Eur"/>
 <result pre="1751â€&quot;1763. doi:10.1183/13993003.01012-201627836953 36GolettiD, Lindestam ArlehamnCS, ScribaTJ, et al.Can we predict" exact="tuberculosis" post="cure? What tools are available?Eur Respir J2018; 52: 1801089."/>
 <result pre="J2018; 52: 1801089. doi:10.1183/13993003.01089-201830361242 37LinPL, FlynnJLCD8 T cells and Mycobacterium" exact="tuberculosis" post="infection. Semin Immunopathol2015; 37: 239â€&quot;249. doi:10.1007/s00281-015-0490-825917388 38ChanJ, MehtaS, BharrhanS,"/>
 <result pre="al.The role of B cells and humoral immunity in Mycobacterium" exact="tuberculosis" post="infection. Semin Immunol2014; 26: 588â€&quot;600. doi:10.1016/j.smim.2014.10.00525458990 39DayCL, AbrahamsDA, LerumoL,"/>
 <result pre="Immunol2011; 187: 2222â€&quot;2232. doi:10.4049/jimmunol.110112221775682 40DayCL, MoshiND, AbrahamsDA, et al.Patients with" exact="tuberculosis" post="disease have Mycobacterium tuberculosis-specific CD8 T cells with a"/>
 <result pre="187: 2222â€&quot;2232. doi:10.4049/jimmunol.110112221775682 40DayCL, MoshiND, AbrahamsDA, et al.Patients with tuberculosis" exact="disease" post="have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic"/>
 <result pre="CD8+ T cells are functionally and phenotypically different between latent" exact="infection" post="and active disease. Eur J Immunol2013; 43: 1568â€&quot;1577. doi:10.1002/eji.20124326223456989"/>
 <result pre="al.Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium" exact="tuberculosis" post="infection. Diagn Microbiol Infect Dis2013; 75: 277â€&quot;281. doi:10.1016/j.diagmicrobio.2012.11.02323276770 44LancioniC,"/>
 <result pre="KiguliS, et al.CD8+ T cells provide an immunologic signature of" exact="tuberculosis" post="in young children. Am J Respir Crit Care Med2012;"/>
 <result pre="496â€&quot;504. doi:10.7589/2013-05-10924779462 46JoostenSA, van MeijgaardenKE, Del NonnoF, et al.Patients with" exact="tuberculosis" post="have a dysfunctional circulating B-cell compartment, which normalizes following"/>
 <result pre="JensenKJ, MonterioI, et al.Rapid protective effects of early BCG on" exact="neonatal" post="mortality among low birth weight boys: observations from randomized"/>
 <result pre="217: 759â€&quot;766. doi:10.1093/infdis/jix61229216358 50NemesE, GeldenhuysH, RozotV, et al.Prevention of M." exact="tuberculosis" post="infection with H4:IC31 vaccine or BCG revaccination. N Engl"/>
 <result pre="759â€&quot;766. doi:10.1093/infdis/jix61229216358 50NemesE, GeldenhuysH, RozotV, et al.Prevention of M. tuberculosis" exact="infection" post="with H4:IC31 vaccine or BCG revaccination. N Engl J"/>
 <result pre="ArtsRJW, van CrevelR, et al.Non-specific effects of BCG vaccine on" exact="viral" post="infections. Clin Microbiol Infect2019; 25: 1473â€&quot;1478. doi:10.1016/j.cmi.2019.04.02031055165 53ArtsRJW, MoorlagS,"/>
 <result pre="doi:10.1016/j.cmi.2019.04.02031055165 53ArtsRJW, MoorlagS, NovakovicB, et al.BCG vaccination protects against experimental" exact="viral infection" post="in humans through the induction of cytokines associated with"/>
 <result pre="53ArtsRJW, MoorlagS, NovakovicB, et al.BCG vaccination protects against experimental viral" exact="infection" post="in humans through the induction of cytokines associated with"/>
 <result pre="e0180143. doi:10.1371/journal.pone.018014328686604 55SpencerJC, GangulyR, WaldmanRHNonspecific protection of mice against influenza" exact="virus infection" post="by local or systemic immunization with Bacille Calmette-Guerin. J"/>
 <result pre="doi:10.1371/journal.pone.018014328686604 55SpencerJC, GangulyR, WaldmanRHNonspecific protection of mice against influenza virus" exact="infection" post="by local or systemic immunization with Bacille Calmette-Guerin. J"/>
 <result pre="protection of mice against influenza virus infection by local or" exact="systemic" post="immunization with Bacille Calmette-Guerin. J Infect Dis1977; 136: 171â€&quot;175."/>
 <result pre="is significantly confounded by age and is unlikely to alter" exact="infection" post="or mortality rates. medRxiv 2020; preprint [10.1101/2020.04.06.20055616]. doi:10.1101/2020.04.06.20055616 60DaoudA,"/>
 <result pre="targeted narrative review. Postgrad Med2019; 131: 299â€&quot;308. doi:10.1080/00325481.2019.159240030845866 61Centers for" exact="Disease" post="Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations,"/>
 <result pre="et al.Critical illness from 2009 pandemic influenza A virus and" exact="bacterial" post="coinfection in the United States. Crit Care Med2012; 40:"/>
 <result pre="65MeterskyML, MastertonRG, LodeH, et al.Epidemiology, microbiology, and treatment considerations for" exact="bacterial pneumonia" post="complicating influenza. Int J Infect Dis2012; 16: e321â€&quot;e331. doi:10.1016/j.ijid.2012.01.00322387143"/>
 <result pre="MastertonRG, LodeH, et al.Epidemiology, microbiology, and treatment considerations for bacterial" exact="pneumonia" post="complicating influenza. Int J Infect Dis2012; 16: e321â€&quot;e331. doi:10.1016/j.ijid.2012.01.00322387143"/>
 <result pre="laboratory and radiologic characteristics of 2009 pandemic influenza A/H1N1 pneumonia:" exact="primary" post="influenza pneumonia versus concomitant/secondary bacterial pneumonia. Influenza Other Respir"/>
 <result pre="radiologic characteristics of 2009 pandemic influenza A/H1N1 pneumonia: primary influenza" exact="pneumonia" post="versus concomitant/secondary bacterial pneumonia. Influenza Other Respir Viruses2011; 5:"/>
 <result pre="2009 pandemic influenza A/H1N1 pneumonia: primary influenza pneumonia versus concomitant/secondary" exact="bacterial pneumonia." post="Influenza Other Respir Viruses2011; 5: e535â€&quot;e543. doi:10.1111/j.1750-2659.2011.00269.x21682848 67MorensDM, TaubenbergerJK,"/>
 <result pre="Respir Viruses2011; 5: e535â€&quot;e543. doi:10.1111/j.1750-2659.2011.00269.x21682848 67MorensDM, TaubenbergerJK, FauciASPredominant role of" exact="bacterial pneumonia" post="as a cause of death in pandemic influenza: implications"/>
 <result pre="Viruses2011; 5: e535â€&quot;e543. doi:10.1111/j.1750-2659.2011.00269.x21682848 67MorensDM, TaubenbergerJK, FauciASPredominant role of bacterial" exact="pneumonia" post="as a cause of death in pandemic influenza: implications"/>
 <result pre="LaiST, PoonLL, et al.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndrome. Lancet2003; 361: 1319â€&quot;1325. doi:10.1016/S0140-6736(03)13077-212711465 71AssiriA, Al-TawfiqJA, Al-RabeeahAA,"/>
 <result pre="PoonLL, et al.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndrome. Lancet2003; 361: 1319â€&quot;1325. doi:10.1016/S0140-6736(03)13077-212711465 71AssiriA, Al-TawfiqJA, Al-RabeeahAA, et"/>
 <result pre="demographic, and clinical characteristics of 47 cases of Middle East" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive study."/>
 <result pre="and clinical characteristics of 47 cases of Middle East respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
 <result pre="characteristics of 47 cases of Middle East respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive study. Lancet Infect Dis2013;"/>
 <result pre="al.Clinical aspects and outcomes of 70 patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a single-center experience in Saudi Arabia."/>
 <result pre="aspects and outcomes of 70 patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a single-center experience in Saudi Arabia. Int"/>
 <result pre="Dis2014; 29: 301â€&quot;306. doi:10.1016/j.ijid.2014.09.00325303830 73Al-TawfiqJA, HinediK, GhandourJ, et al.Middle East" exact="respiratory" post="syndrome coronavirus: a case-control study of hospitalized patients. Clin"/>
 <result pre="29: 301â€&quot;306. doi:10.1016/j.ijid.2014.09.00325303830 73Al-TawfiqJA, HinediK, GhandourJ, et al.Middle East respiratory" exact="syndrome" post="coronavirus: a case-control study of hospitalized patients. Clin Infect"/>
 <result pre="Clin Infect Dis2014; 59: 160â€&quot;165. doi:10.1093/cid/ciu22624723278 74ZumlaA, HuiDS, PerlmanSMiddle East" exact="respiratory" post="syndrome. Lancet2015; 386: 995â€&quot;1007. doi:10.1016/S0140-6736(15)60454-826049252 75LiW, MooreMJ, VasilievaN, et"/>
 <result pre="World Health OrganizationEmergency preparedness, response: preliminary clinical description of severe" exact="acute" post="respiratory syndrome. Geneva, WHO, 2003. 77PeirisJS, ChuCM, ChengVC, et"/>
 <result pre="Health OrganizationEmergency preparedness, response: preliminary clinical description of severe acute" exact="respiratory" post="syndrome. Geneva, WHO, 2003. 77PeirisJS, ChuCM, ChengVC, et al.Clinical"/>
 <result pre="Geneva, WHO, 2003. 77PeirisJS, ChuCM, ChengVC, et al.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
 <result pre="van RielD, et al.The pathology and pathogenesis of experimental severe" exact="acute" post="respiratory syndrome and influenza in animal models. J Comp"/>
 <result pre="RielD, et al.The pathology and pathogenesis of experimental severe acute" exact="respiratory" post="syndrome and influenza in animal models. J Comp Pathol2014;"/>
 <result pre="et al.The pathology and pathogenesis of experimental severe acute respiratory" exact="syndrome" post="and influenza in animal models. J Comp Pathol2014; 151:"/>
 <result pre="course and outcomes of critically ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infection. Ann Intern Med2014; 160: 389â€&quot;397. doi:10.7326/M13-248624474051"/>
 <result pre="and outcomes of critically ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infection. Ann Intern Med2014; 160: 389â€&quot;397. doi:10.7326/M13-248624474051 82GuanWJ,"/>
 <result pre="389â€&quot;397. doi:10.7326/M13-248624474051 82GuanWJ, NiZY, HuY, et al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med2020; 382: 1708â€&quot;1720."/>
 <result pre="DuR, et al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="doi:10.1016/S0140-6736(20)30566-332171076 85WuZ, McGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and Prevention. JAMA2020; 323: 1239â€&quot;1242. doi:10.1001/jama.2020.264832091533 86AlhazzaniW, MollerMH,"/>
 <result pre="guidelines on the management of critically ill adults with coronavirus" exact="disease" post="2019 (COVID-19). Crit Care Med2020; 46: 854â€&quot;887. doi:10.1007/s00134-020-06022-5 87VitaccaM,"/>
 <result pre="Infect Dis2020; 71: 1547â€&quot;1551. doi:10.1093/cid/ciaa19832112072 89LuX, ZhangL, DuH, et al.SARS-CoV-2" exact="infection" post="in children. N Engl J Med2020; 382: 1663â€&quot;1665. doi:10.1056/NEJMc200507332187458"/>
 <result pre="Med2020; 382: 1663â€&quot;1665. doi:10.1056/NEJMc200507332187458 90CuiY, TianM, HuangD, et al.A 55-day-old" exact="female" post="infant infected with COVID 19: presenting with pneumonia, liver"/>
 <result pre="infant infected with COVID 19: presenting with pneumonia, liver injury," exact="and heart" post="damage. J Infect Dis2020; 221: 1775â€&quot;1781. doi:10.1093/infdis/jiaa11332179908 91LiuW, ZhangQ,"/>
 <result pre="infected with COVID 19: presenting with pneumonia, liver injury, and" exact="heart" post="damage. J Infect Dis2020; 221: 1775â€&quot;1781. doi:10.1093/infdis/jiaa11332179908 91LiuW, ZhangQ,"/>
 <result pre="WangT, et al.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: expertsâ€™ consensus statement. World J Pediatr2020; 16:"/>
 <result pre="World J Pediatr2020; 16: 223â€&quot;231. doi:10.1007/s12519-020-00343-732034659 93collab: European Centre for" exact="Disease" post="Prevention and ControlGuidelines for the use of non-pharmaceutical measures"/>
 <result pre="NiuL, et al.Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19)" exact="pneumonia" post="in two patients with lung cancer. J Thorac Oncol2020;"/>
 <result pre="early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with" exact="lung cancer." post="J Thorac Oncol2020; 15: 700â€&quot;704. doi:10.1016/j.jtho.2020.02.01032114094 98FoxSE, AkmatbekovA, HarbertJL,"/>
 <result pre="from New Orleans. medRxiv 2020; preprint [10.1101/2020.04.06.20050575]. doi:10.1101/2020.04.06.20050575 99collab: International" exact="Severe" post="Acute Respiratory and Emerging Infections ConsortiumCOVID-19 Report: 27 April"/>
 <result pre="New Orleans. medRxiv 2020; preprint [10.1101/2020.04.06.20050575]. doi:10.1101/2020.04.06.20050575 99collab: International Severe" exact="Acute" post="Respiratory and Emerging Infections ConsortiumCOVID-19 Report: 27 April 2020https://media.tghn.org/medialibrary/2020/05/ISARIC_Data_Platform_COVID-19_Report_27APR20.pdfDate"/>
 <result pre="Orleans. medRxiv 2020; preprint [10.1101/2020.04.06.20050575]. doi:10.1101/2020.04.06.20050575 99collab: International Severe Acute" exact="Respiratory" post="and Emerging Infections ConsortiumCOVID-19 Report: 27 April 2020https://media.tghn.org/medialibrary/2020/05/ISARIC_Data_Platform_COVID-19_Report_27APR20.pdfDate last"/>
 <result pre="preprint [10.1101/2020.04.06.20050575]. doi:10.1101/2020.04.06.20050575 99collab: International Severe Acute Respiratory and Emerging" exact="Infections" post="ConsortiumCOVID-19 Report: 27 April 2020https://media.tghn.org/medialibrary/2020/05/ISARIC_Data_Platform_COVID-19_Report_27APR20.pdfDate last accessed: July 7,"/>
 <result pre="researchers. Eur Respir J2020; 55: 2001028. doi:10.1183/13993003.01028-202032341111 101TokmanS, HuangLEvaluation of" exact="respiratory" post="disease. Clin Chest Med2013; 34: 191â€&quot;204. doi:10.1016/j.ccm.2013.02.00523702170 102AzoulayE, de"/>
 <result pre="Chest2020; 157: 293â€&quot;309. doi:10.1016/j.chest.2019.08.00231421114 103SegalLN, MetheBA, NolanA, et al.HIV-1 and" exact="bacterial pneumonia" post="in the era of antiretroviral therapy. Proc Am Thorac"/>
 <result pre="157: 293â€&quot;309. doi:10.1016/j.chest.2019.08.00231421114 103SegalLN, MetheBA, NolanA, et al.HIV-1 and bacterial" exact="pneumonia" post="in the era of antiretroviral therapy. Proc Am Thorac"/>
 <result pre="ChakayaJ, SwaminathanS, et al.Tackling long-term morbidity and mortality after successful" exact="tuberculosis" post="treatment. Lancet Infect Dis2020; 20: 641â€&quot;642. doi:10.1016/S1473-3099(20)30167-532213333 105PasipanodyaJG, MillerTL,"/>
 <result pre="doi:10.1378/chest.06-294917400690 106WalazaS, TempiaS, DawoodH, et al.The impact of influenza and" exact="tuberculosis" post="interaction on mortality among individuals aged â‰¥â€‰15 years hospitalized"/>
 <result pre="on mortality among individuals aged â‰¥â€‰15 years hospitalized with severe" exact="respiratory" post="illness in South Africa, 2010â€&quot;2016. Open Forum Infect Dis2019;"/>
 <result pre="107WalazaS, CohenC, NanooA, et al.Excess mortality associated with influenza among" exact="tuberculosis" post="deaths in South Africa, 1999â€&quot;2009. PLoS One2015; 10: e0129173."/>
 <result pre="doi:10.1371/journal.pone.012917326076197 108MhimbiraF, HizaH, MbubaE, et al.Prevalence and clinical significance of" exact="respiratory" post="viruses and bacteria detected in tuberculosis patients compared to"/>
 <result pre="and clinical significance of respiratory viruses and bacteria detected in" exact="tuberculosis" post="patients compared to household contact controls in Tanzania: a"/>
 <result pre="after influenza. Cal State J Med1919; 17: 85.18737838 110BallingerMN, StandifordTJPostinfluenza" exact="bacterial" post="pneumonia: host defenses gone awry. J Interferon Cytokine Res2010;"/>
 <result pre="doi:10.1089/jir.2010.004920726789 111ParkY, ChinBS, HanSH, et al.Pandemic influenza (H1N1) and Mycobacterium" exact="tuberculosis" post="co-infection. Tuberc Respir Dis2014; 76: 84â€&quot;87. doi:10.4046/trd.2014.76.2.84 112ZurcherK, ZwahlenM,"/>
 <result pre="76: 84â€&quot;87. doi:10.4046/trd.2014.76.2.84 112ZurcherK, ZwahlenM, BallifM, et al.Influenza pandemics and" exact="tuberculosis" post="mortality in 1889 and 1918: analysis of historical data"/>
 <result pre="11: e0162575. doi:10.1371/journal.pone.016257527706149 113LuoT, SumiA, ZhouD, et al.Seasonality of reported" exact="tuberculosis" post="cases from 2006 to 2010 in Wuhan, China. Epidemiol"/>
 <result pre="Infect2014; 142: 2036â€&quot;2048. doi:10.1017/S095026881300314224331081 114RothS, WhiteheadS, ThamthitiwatS, et al.Concurrent influenza" exact="virus infection" post="and tuberculosis in patients hospitalized with respiratory illness in"/>
 <result pre="142: 2036â€&quot;2048. doi:10.1017/S095026881300314224331081 114RothS, WhiteheadS, ThamthitiwatS, et al.Concurrent influenza virus" exact="infection" post="and tuberculosis in patients hospitalized with respiratory illness in"/>
 <result pre="doi:10.1017/S095026881300314224331081 114RothS, WhiteheadS, ThamthitiwatS, et al.Concurrent influenza virus infection and" exact="tuberculosis" post="in patients hospitalized with respiratory illness in Thailand. Influenza"/>
 <result pre="al.Concurrent influenza virus infection and tuberculosis in patients hospitalized with" exact="respiratory" post="illness in Thailand. Influenza Other Respir Viruses2013; 7: 244â€&quot;248."/>
 <result pre="van CrevelR, van BeekR, et al.The influence of influenza virus" exact="infections" post="on the development of tuberculosis. Tuberculosis2013; 93: 338â€&quot;342. doi:10.1016/j.tube.2013.02.00623474302"/>
 <result pre="338â€&quot;342. doi:10.1016/j.tube.2013.02.00623474302 116YenYF, PanSW, SuVY, et al.Influenza vaccination and incident" exact="tuberculosis" post="among elderly persons, Taiwan. Emerging Infect Dis2018; 24: 498â€&quot;505."/>
 <result pre="World Health OrganizationWHO consolidated guidelines on tuberculosis: module 1: prevention:" exact="tuberculosis" post="preventive treatment. Geneva, WHO, 2020. 120collab: World Health OrganizationWHO"/>
 <result pre="World Health OrganizationWHO operational handbook on tuberculosis: module 1: prevention:" exact="tuberculosis" post="preventive treatment. Geneva, WHO, 2020. 121collab: World Health OrganizationWHO"/>
 <result pre="other stakeholders. Geneva, WHO, 2012. 122LiuW, FontanetA, ZhangPH, et al.Pulmonary" exact="tuberculosis" post="and SARS, China. Emerging Infect Dis2006; 12: 707â€&quot;709. doi:10.3201/eid1204.050264"/>
 <result pre="Infect Dis2006; 12: 707â€&quot;709. doi:10.3201/eid1204.050264 123LowJG, LeeCC, LeoYS, et al.Severe" exact="acute" post="respiratory syndrome and pulmonary tuberculosis. Clin Infect Dis2004; 38:"/>
 <result pre="Dis2006; 12: 707â€&quot;709. doi:10.3201/eid1204.050264 123LowJG, LeeCC, LeoYS, et al.Severe acute" exact="respiratory" post="syndrome and pulmonary tuberculosis. Clin Infect Dis2004; 38: e123â€&quot;e125."/>
 <result pre="12: 707â€&quot;709. doi:10.3201/eid1204.050264 123LowJG, LeeCC, LeoYS, et al.Severe acute respiratory" exact="syndrome" post="and pulmonary tuberculosis. Clin Infect Dis2004; 38: e123â€&quot;e125. doi:10.1086/42139615227635"/>
 <result pre="doi:10.3201/eid1204.050264 123LowJG, LeeCC, LeoYS, et al.Severe acute respiratory syndrome and" exact="pulmonary" post="tuberculosis. Clin Infect Dis2004; 38: e123â€&quot;e125. doi:10.1086/42139615227635 124CuiW, FanY,"/>
 <result pre="al.Expression of lymphocytes and lymphocyte subsets in patients with severe" exact="acute" post="respiratory syndrome. Clin Infect Dis2003; 37: 857â€&quot;859. doi:10.1086/37858712955652 125GolettiD,"/>
 <result pre="of lymphocytes and lymphocyte subsets in patients with severe acute" exact="respiratory" post="syndrome. Clin Infect Dis2003; 37: 857â€&quot;859. doi:10.1086/37858712955652 125GolettiD, LeeMR,"/>
 <result pre="Dis2003; 37: 857â€&quot;859. doi:10.1086/37858712955652 125GolettiD, LeeMR, WangJY, et al.Update on" exact="tuberculosis" post="biomarkers: from correlates of risk, to correlates of active"/>
 <result pre="tuberculosis biomarkers: from correlates of risk, to correlates of active" exact="disease" post="and of cure from disease. Respirology2018; 23: 455â€&quot;466. doi:10.1111/resp.1327229457312"/>
 <result pre="of human pathogen-specific CD4 T cell responses in healthy M." exact="tuberculosis" post="infected South Africans. PLoS Pathog2016; 12: e1005760. doi:10.1371/journal.ppat.100576027409590 127PetruccioliE,"/>
 <result pre="475â€&quot;486. doi:10.1016/j.jinf.2013.02.00423462597 128ChiacchioT, PetruccioliE, VaniniV, et al.Impact of antiretroviral and" exact="tuberculosis" post="therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in"/>
 <result pre="al.Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active" exact="tuberculosis" post="and latent infection. J Infect2020; 80: 536â€&quot;546. doi:10.1016/j.jinf.2020.02.00932097688 130WongCY,"/>
 <result pre="of the global COVID-19 outbreak on the management of other" exact="communicable diseases." post="Int J Tuberc Lung Dis2020; 24: 547â€&quot;548. doi:10.5588/ijtld.20.014032398214 132AlfarajSH,"/>
 <result pre="Dis2020; 24: 547â€&quot;548. doi:10.5588/ijtld.20.014032398214 132AlfarajSH, Al-TawfiqJA, AltuwaijriTA, et al.Middle East" exact="respiratory" post="syndrome coronavirus and pulmonary tuberculosis coinfection: implications for infection"/>
 <result pre="24: 547â€&quot;548. doi:10.5588/ijtld.20.014032398214 132AlfarajSH, Al-TawfiqJA, AltuwaijriTA, et al.Middle East respiratory" exact="syndrome" post="coronavirus and pulmonary tuberculosis coinfection: implications for infection control."/>
 <result pre="132AlfarajSH, Al-TawfiqJA, AltuwaijriTA, et al.Middle East respiratory syndrome coronavirus and" exact="pulmonary" post="tuberculosis coinfection: implications for infection control. Intervirology2017; 60: 53â€&quot;55."/>
 <result pre="Al-TawfiqJA, AltuwaijriTA, et al.Middle East respiratory syndrome coronavirus and pulmonary" exact="tuberculosis" post="coinfection: implications for infection control. Intervirology2017; 60: 53â€&quot;55. doi:10.1159/00047790828683463"/>
 <result pre="East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for" exact="infection" post="control. Intervirology2017; 60: 53â€&quot;55. doi:10.1159/00047790828683463 133LiuY, BiL, ChenY, et"/>
 <result pre="60: 53â€&quot;55. doi:10.1159/00047790828683463 133LiuY, BiL, ChenY, et al.Active or latent" exact="tuberculosis" post="increases susceptibility to COVID-19 and disease severity. medRxiv2020; preprint"/>
 <result pre="doi:10.1159/00047790828683463 133LiuY, BiL, ChenY, et al.Active or latent tuberculosis increases" exact="susceptibility to" post="COVID-19 and disease severity. medRxiv2020; preprint [10.1101/2020.03.10.20033795]. doi:10.1101/2020.03.10.20033795 134MacielELN,"/>
 <result pre="et al.Active or latent tuberculosis increases susceptibility to COVID-19 and" exact="disease" post="severity. medRxiv2020; preprint [10.1101/2020.03.10.20033795]. doi:10.1101/2020.03.10.20033795 134MacielELN, GoncalvesEJ, DalcolmoMMPTuberculosis and"/>
 <result pre="cohorts. Pulmonology2020; 26: 233â€&quot;240. doi:10.1016/j.pulmoe.2020.05.00232411943 137AultR, DwivediV, KoivistoE, et al.Altered" exact="monocyte" post="phenotypes but not impaired peripheral T cell immunity may"/>
 <result pre="137AultR, DwivediV, KoivistoE, et al.Altered monocyte phenotypes but not impaired" exact="peripheral" post="T cell immunity may explain susceptibility of the elderly"/>
 <result pre="Gerontol2018; 111: 35â€&quot;44. doi:10.1016/j.exger.2018.06.02929991459 138collab: Epidemiology Working Group for NCIP" exact="Epidemic" post="Response, Chinese Center for Disease Control and Prevention[The epidemiological"/>
 <result pre="Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for" exact="Disease" post="Control and Prevention[The epidemiological characteristics of an outbreak of"/>
 <result pre="Geneva, WHO, 2013. 142JamiesonDJ, HoneinMA, RasmussenSA, et al.H1N1 2009 influenza" exact="virus infection" post="during pregnancy in the USA. Lancet2009; 374: 451â€&quot;458. doi:10.1016/S0140-6736(09)61304-019643469"/>
 <result pre="WHO, 2013. 142JamiesonDJ, HoneinMA, RasmussenSA, et al.H1N1 2009 influenza virus" exact="infection" post="during pregnancy in the USA. Lancet2009; 374: 451â€&quot;458. doi:10.1016/S0140-6736(09)61304-019643469"/>
 <result pre="FarinasMC, et al.Immunosuppressed patients with pandemic influenza A 2009 (H1N1)" exact="virus infection." post="Eur J Clin Microbiol Infect Dis2012; 31: 547â€&quot;556. doi:10.1007/s10096-011-1346-321792558"/>
 <result pre="Infect Dis2012; 31: 547â€&quot;556. doi:10.1007/s10096-011-1346-321792558 144MathadJS, GuptaATuberculosis in pregnant and" exact="postpartum" post="women: epidemiology, management, and research gaps. Clin Infect Dis2012;"/>
 <result pre="notice. Int J Infect Dis2015; 32: 135â€&quot;137. doi:10.1016/j.ijid.2014.11.01825809769 148PinskyBA, HaydenRTCost-effective" exact="respiratory" post="virus testing. J Clin Microbiol2019; 57: e00373-19. doi:10.1128/JCM.00373-1931142607 149AlmekhlafiGA,"/>
 <result pre="149AlmekhlafiGA, AlbarrakMM, MandourahY, et al.Presentation and outcome of Middle East" exact="respiratory" post="syndrome in Saudi intensive care unit patients. Crit Care2016;"/>
 <result pre="AlbarrakMM, MandourahY, et al.Presentation and outcome of Middle East respiratory" exact="syndrome" post="in Saudi intensive care unit patients. Crit Care2016; 20:"/>
 <result pre="area. JAMA2003; 289: 2801â€&quot;2809. doi:10.1001/jama.289.21.JOC3088512734147 151MidgleyCM, JacksonMA, SelvaranganR, et al.Severe" exact="respiratory" post="illness associated with enterovirus D68 â€&quot; Missouri and Illinois,"/>
 <result pre="152ZhuN, ZhangD, WangW, et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med2020; 382: 727â€&quot;733."/>
 <result pre="profile of the humoral immune response to influenza vaccination in" exact="breast cancer" post="patients treated with chemotherapy. Vaccine2017; 35: 1299â€&quot;1305. doi:10.1016/j.vaccine.2017.01.03928169075 154GoodwinS,"/>
 <result pre="of the humoral immune response to influenza vaccination in breast" exact="cancer" post="patients treated with chemotherapy. Vaccine2017; 35: 1299â€&quot;1305. doi:10.1016/j.vaccine.2017.01.03928169075 154GoodwinS,"/>
 <result pre="et al.High resolution metagenomic characterization of complex infectomes in paediatric" exact="acute" post="respiratory infection. Sci Rep2020; 10: 3963. doi:10.1038/s41598-020-60992-632127629 156KufnerV, PlateA,"/>
 <result pre="al.High resolution metagenomic characterization of complex infectomes in paediatric acute" exact="respiratory" post="infection. Sci Rep2020; 10: 3963. doi:10.1038/s41598-020-60992-632127629 156KufnerV, PlateA, SchmutzS,"/>
 <result pre="10: 3963. doi:10.1038/s41598-020-60992-632127629 156KufnerV, PlateA, SchmutzS, et al.Two years of" exact="viral" post="metagenomics in a tertiary diagnostics unit: evaluation of the"/>
 <result pre="the first 105 cases. Genes2019; 10: 661. doi:10.3390/genes10090661 157Gillim-RossL, SubbaraoKEmerging" exact="respiratory" post="viruses: challenges and vaccine strategies. Clin Microbiol Rev2006; 19:"/>
 <result pre="MTB/RIF and decentralized care on linkage to care and drug-resistant" exact="tuberculosis" post="treatment outcomes in Johannesburg, South Africa. BMC Health Serv"/>
 <result pre="91: 24â€&quot;31. doi:10.3899/jrheum.14009924788997 161collab: World Health OrganizationClinical management of severe" exact="acute" post="respiratory infection when COVID-19 is suspected: interim guidance. Geneva,"/>
 <result pre="24â€&quot;31. doi:10.3899/jrheum.14009924788997 161collab: World Health OrganizationClinical management of severe acute" exact="respiratory" post="infection when COVID-19 is suspected: interim guidance. Geneva, WHO,"/>
 <result pre="doi:10.3899/jrheum.14009924788997 161collab: World Health OrganizationClinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected: interim guidance. Geneva, WHO, 2020."/>
 <result pre="COVID-19 is suspected: interim guidance. Geneva, WHO, 2020. 162McCrearyEK, PogueJMCoronavirus" exact="disease" post="2019 treatment: a review of early and emerging options."/>
 <result pre="options. Open Forum Infect Dis2020; 7: ofaa10510.1093/ofid/ofaa10532284951 163HaganG, NathaniNClinical review:" exact="tuberculosis" post="on the intensive care unit. Crit Care2013; 17: 240."/>
 <result pre="LeeJ, et al.Lopinavirâ€&quot;ritonavir super-boosting in young HIV-infected children on rifampicin-based" exact="tuberculosis" post="therapy compared with lopinavirâ€&quot;ritonavir without rifampicin: a pharmacokinetic modelling"/>
 <result pre="trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated" exact="tuberculosis" post="in Vietnam. PLoS One2014; 9: e84866. doi:10.1371/journal.pone.008486624465443 168PrincipiN, EspositoSChloroquine"/>
 <result pre="Rheumatology2006; 45: 703â€&quot;710. doi:10.1093/rheumatology/kei28216418198 172Ben-ZviI, KivityS, LangevitzP, et al.Hydroxychloroquine: from" exact="malaria" post="to autoimmunity. Clin Rev Allergy Immunol2012; 42: 145â€&quot;153. doi:10.1007/s12016-010-8243-x21221847"/>
 <result pre="145â€&quot;153. doi:10.1007/s12016-010-8243-x21221847 173SavarinoA, BoelaertJR, CassoneA, et al.Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases?Lancet Infect Dis2003;"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial."/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA"/>
 <result pre="hospital setting or a clinical trial due to risk of" exact="heart" post="rhythm problems2020www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-orDate last accessed: May 4, 2020. 176DucharmeJ, FarinottiRClinical"/>
 <result pre="PivaS, CattaliniM, et al.Tocilizumab for the treatment of severe COVID-19" exact="pneumonia" post="with hyperinflammatory syndrome and acute respiratory failure: a single"/>
 <result pre="al.Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory" exact="syndrome" post="and acute respiratory failure: a single center study of"/>
 <result pre="the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and" exact="acute" post="respiratory failure: a single center study of 100 patients"/>
 <result pre="treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute" exact="respiratory" post="failure: a single center study of 100 patients in"/>
 <result pre="Infect2020; 81: 318â€&quot;356. doi:10.1016/j.jinf.2020.04.017 179WengD, WuQ, ChenXQ, et al.Azithromycin treats" exact="diffuse" post="panbronchiolitis by targeting T cells via inhibition of mTOR"/>
 <result pre="of arbidol and its derivatives against the pathogen of severe" exact="acute" post="respiratory syndrome in the cell cultures]. Vopr Virusol2008; 53:"/>
 <result pre="arbidol and its derivatives against the pathogen of severe acute" exact="respiratory" post="syndrome in the cell cultures]. Vopr Virusol2008; 53: 9â€&quot;13."/>
 <result pre="and its derivatives against the pathogen of severe acute respiratory" exact="syndrome" post="in the cell cultures]. Vopr Virusol2008; 53: 9â€&quot;13. 185DengL,"/>
 <result pre="et al.Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: a retrospective cohort study. J Infect2020; 81: e1â€&quot;e5."/>
 <result pre="al.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: a retrospective cohort study. J Infect2020; 81: e1â€&quot;e5."/>
 <result pre="Sci USA2007; 104: 7582â€&quot;7587. doi:10.1073/pnas.061094110417416679 188MiglioriGB, NardellE, YedilbayevA, et al.Reducing" exact="tuberculosis" post="transmission: a consensus document from the World Health Organization"/>
 <result pre="J2019; 53: 1900391. doi:10.1183/13993003.00391-201931023852 189collab: World Health OrganizationWHO guidelines on" exact="tuberculosis" post="infection prevention and control: 2019 update. Geneva, WHO, 2019."/>
 <result pre="53: 1900391. doi:10.1183/13993003.00391-201931023852 189collab: World Health OrganizationWHO guidelines on tuberculosis" exact="infection" post="prevention and control: 2019 update. Geneva, WHO, 2019. 190ThorneCD,"/>
 <result pre="McDiarmidMAUsing the hierarchy of control technologies to improve healthcare facility" exact="infection" post="control: lessons from severe acute respiratory syndrome. J Occup"/>
 <result pre="technologies to improve healthcare facility infection control: lessons from severe" exact="acute" post="respiratory syndrome. J Occup Environ Med2004; 46: 613â€&quot;622. doi:10.1097/01.jom.0000134191.92225.f215247800"/>
 <result pre="to improve healthcare facility infection control: lessons from severe acute" exact="respiratory" post="syndrome. J Occup Environ Med2004; 46: 613â€&quot;622. doi:10.1097/01.jom.0000134191.92225.f215247800 191BaiY,"/>
 <result pre="COVID-19. JAMA2020; 323: 1406â€&quot;1407. doi:10.1001/jama.2020.256532083643 192ZouL, RuanF, HuangM, et al.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patients. N"/>
 <result pre="1406â€&quot;1407. doi:10.1001/jama.2020.256532083643 192ZouL, RuanF, HuangM, et al.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patients. N Engl J Med2020;"/>
 <result pre="doi:10.1001/jama.2020.256532083643 192ZouL, RuanF, HuangM, et al.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patients. N Engl J Med2020; 382:"/>
 <result pre="Eur Respir J2020; 55: 2001260. doi:10.1183/13993003.01260-202032350103 198collab: European Centre for" exact="Disease" post="Prevention and ControlUsing face masks in the community: reducing"/>
 <result pre="precaution recommendations. Geneva, WHO, 2020. 201LaiMY, ChengPK, LimWWSurvival of severe" exact="acute" post="respiratory syndrome coronavirus. Clin Infect Dis2005; 41: e67â€&quot;e71. doi:10.1086/43318616142653"/>
 <result pre="recommendations. Geneva, WHO, 2020. 201LaiMY, ChengPK, LimWWSurvival of severe acute" exact="respiratory" post="syndrome coronavirus. Clin Infect Dis2005; 41: e67â€&quot;e71. doi:10.1086/43318616142653 202RabenauHF,"/>
 <result pre="Geneva, WHO, 2020. 201LaiMY, ChengPK, LimWWSurvival of severe acute respiratory" exact="syndrome" post="coronavirus. Clin Infect Dis2005; 41: e67â€&quot;e71. doi:10.1086/43318616142653 202RabenauHF, CinatlJ,"/>
 <result pre="Med Microbiol Immunol2005; 194: 1â€&quot;6. doi:10.1007/s00430-004-0219-015118911 203collab: European Centre for" exact="Disease" post="Prevention and ControlDisinfection of environments in healthcare and nonhealthcare"/>
 <result pre="Biomed Environ Sci2003; 16: 246â€&quot;255.14631830 205BergerA, DrostenC, DoerrHW, et al.Severe" exact="acute" post="respiratory syndrome (SARS) â€&quot; paradigm of an emerging viral"/>
 <result pre="Environ Sci2003; 16: 246â€&quot;255.14631830 205BergerA, DrostenC, DoerrHW, et al.Severe acute" exact="respiratory" post="syndrome (SARS) â€&quot; paradigm of an emerging viral infection."/>
 <result pre="Sci2003; 16: 246â€&quot;255.14631830 205BergerA, DrostenC, DoerrHW, et al.Severe acute respiratory" exact="syndrome" post="(SARS) â€&quot; paradigm of an emerging viral infection. J"/>
 <result pre="al.Severe acute respiratory syndrome (SARS) â€&quot; paradigm of an emerging" exact="viral infection." post="J Clin Virol2004; 29: 13â€&quot;22. doi:10.1016/j.jcv.2003.09.01114675864 206BonnyTS, YezliS, LednickyJAIsolation"/>
 <result pre="SotgiuG, ReichlerMR, et al.New diseases and old threats: lessons from" exact="tuberculosis" post="for the COVID-19 response. Int J Tuberc Lung Dis2020;"/>
 <result pre="ThomasE, SnoswellCL, et al.Telehealth for global emergencies: Implications for coronavirus" exact="disease" post="2019 (COVID-19). J Telemed Telecare2020; 26: 309â€&quot;313. doi:10.1177/1357633X2091656732196391 213collab:"/>
 <result pre="J Public Health2010; 55: 459â€&quot;468. doi:10.1007/s00038-010-0149-020467882 215collab: European Centre for" exact="Disease" post="Prevention and ControlCoronavirus disease 2019 (COVID-19) in the EU/EEA"/>
 <result pre="459â€&quot;468. doi:10.1007/s00038-010-0149-020467882 215collab: European Centre for Disease Prevention and ControlCoronavirus" exact="disease" post="2019 (COVID-19) in the EU/EEA and the UK â€&quot;"/>
 <result pre="update. Stockholm, ECDC, 2020. 216collab: World Health OrganizationWHO Information note:" exact="tuberculosis" post="and COVID-19. Geneva, WHO, 2020. 217SooRJJ, ChiewCJ, MaS, et"/>
 <result pre="al.The impact of social protection and poverty elimination on global" exact="tuberculosis" post="incidence: a statistical modelling analysis of Sustainable Development Goal"/>
 <result pre="Garcia-BasteiroALPredicting the effect of improved socioeconomic health determinants on the" exact="tuberculosis" post="epidemic. Lancet Glob Health2018; 6: e475â€&quot;e476. doi:10.1016/S2214-109X(18)30189-X29580762 222collab: World"/>
 <result pre="6: e475â€&quot;e476. doi:10.1016/S2214-109X(18)30189-X29580762 222collab: World Health OrganizationReport of the WHOâ€&quot;China" exact="Joint" post="Mission on Coronavirus Disease 2019 (COVID-19).Geneva, WHO, 2020. 223collab:"/>
 <result pre="World Health OrganizationReport of the WHOâ€&quot;China Joint Mission on Coronavirus" exact="Disease" post="2019 (COVID-19).Geneva, WHO, 2020. 223collab: Centers for Disease Control"/>
 <result pre="on Coronavirus Disease 2019 (COVID-19).Geneva, WHO, 2020. 223collab: Centers for" exact="Disease" post="Control and PreventionGuidelines for environmental infection control in health-care"/>
 <result pre="2020. 223collab: Centers for Disease Control and PreventionGuidelines for environmental" exact="infection" post="control in health-care facilities2003www.cdc.gov/infectioncontrol/guidelines/environmental/index.htmlDate last accessed: July 7, 2020"/>
 <result pre="Crit Care Med2012; 185: 1104â€&quot;1109. doi:10.1164/rccm.201107-1190OC22323300 225collab: European Centre for" exact="Disease" post="Prevention and ControlCloth masks and mask sterilisation as options"/>
 <result pre="230RichardsonP, GriffinI, TuckerC, et al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet2020; 395: e30â€&quot;e31. doi:10.1016/S0140-6736(20)30304-432032529 231MorseJS, LalondeT, XuS,"/>
 <result pre="GriffinI, TuckerC, et al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet2020; 395: e30â€&quot;e31. doi:10.1016/S0140-6736(20)30304-432032529 231MorseJS, LalondeT, XuS, et"/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. Chembiochem2020; 21: 730â€&quot;738. doi:10.1002/cbic.20200004732022370"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. Chembiochem2020; 21: 730â€&quot;738. doi:10.1002/cbic.20200004732022370 232JordanPC,"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. Chembiochem2020; 21: 730â€&quot;738. doi:10.1002/cbic.20200004732022370 232JordanPC, StevensSK,"/>
 <result pre="21: 730â€&quot;738. doi:10.1002/cbic.20200004732022370 232JordanPC, StevensSK, DevalJNucleosides for the treatment of" exact="respiratory" post="RNA virus infections. Antivir Chem Chemother2018; 26: 2040206618764483. doi:10.1177/204020661876448329562753"/>
 <result pre="2040206618764483. doi:10.1177/204020661876448329562753 233FurutaY, GowenBB, TakahashiK, et al.Favipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitor. Antiviral Res2013; 100: 446â€&quot;454. doi:10.1016/j.antiviral.2013.09.01524084488 234ShirakiK,"/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem2020; 295: 4773â€&quot;4779. doi:10.1074/jbc.AC120.01305632094225 238BustiAJ,"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem2020; 295: 4773â€&quot;4779. doi:10.1074/jbc.AC120.01305632094225 238BustiAJ, HallRG,"/>
 <result pre="4773â€&quot;4779. doi:10.1074/jbc.AC120.01305632094225 238BustiAJ, HallRG, MargolisDMAtazanavir for the treatment of human" exact="immunodeficiency" post="virus infection. Pharmacotherapy2004; 24: 1732â€&quot;1747. doi:10.1592/phco.24.17.1732.5234715585441 239collab: Shionogi &amp;amp;"/>
 <result pre="doi:10.1074/jbc.AC120.01305632094225 238BustiAJ, HallRG, MargolisDMAtazanavir for the treatment of human immunodeficiency" exact="virus infection." post="Pharmacotherapy2004; 24: 1732â€&quot;1747. doi:10.1592/phco.24.17.1732.5234715585441 239collab: Shionogi &amp;amp; Co. LtdReview"/>
 <result pre="NarbuttJSeizures as a rare adverse effect of chloroquine therapy in" exact="systemic" post="lupus erythematosus patients: a case report and literature survey."/>
 <result pre="as a rare adverse effect of chloroquine therapy in systemic" exact="lupus erythematosus" post="patients: a case report and literature survey. Postepy Dermatol"/>
 <result pre="Clin Rheumatol2007; 26: 1809â€&quot;1810. doi:10.1007/s10067-007-0662-617594118 250MalcangiG, FraticelliP, PalmieriC, et al.Hydroxychloroquine-induced" exact="seizure" post="in a patient with systemic lupus erythematosus. Rheumatol Int2000;"/>
 <result pre="250MalcangiG, FraticelliP, PalmieriC, et al.Hydroxychloroquine-induced seizure in a patient with" exact="systemic" post="lupus erythematosus. Rheumatol Int2000; 20: 31â€&quot;33. doi:10.1007/s00296000006611149659 251ZamoranoJL, LancellottiP,"/>
 <result pre="FraticelliP, PalmieriC, et al.Hydroxychloroquine-induced seizure in a patient with systemic" exact="lupus erythematosus." post="Rheumatol Int2000; 20: 31â€&quot;33. doi:10.1007/s00296000006611149659 251ZamoranoJL, LancellottiP, Rodriguez MunozD,"/>
 <result pre="251ZamoranoJL, LancellottiP, Rodriguez MunozD, et al.2016 ESC Position Paper on" exact="cancer" post="treatments and cardiovascular toxicity developed under the auspices of"/>
 <result pre="MunozD, et al.2016 ESC Position Paper on cancer treatments and" exact="cardiovascular" post="toxicity developed under the auspices of the ESC Committee"/>
 <result pre="the ESC Committee for Practice Guidelines: The Task Force for" exact="cancer" post="treatments and cardiovascular toxicity of the European Society of"/>
 <result pre="for Practice Guidelines: The Task Force for cancer treatments and" exact="cardiovascular" post="toxicity of the European Society of Cardiology (ESC). Eur"/>
 <result pre="cardiovascular toxicity of the European Society of Cardiology (ESC). Eur" exact="Heart" post="J2016; 37: 2768â€&quot;2801. doi:10.1093/eurheartj/ehw21127567406 252ShakilAO, Di BisceglieAM, HoofnagleJHSeizures during"/>
</results>
